0001144204-18-059762.txt : 20181114 0001144204-18-059762.hdr.sgml : 20181114 20181114135045 ACCESSION NUMBER: 0001144204-18-059762 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 36 CONFORMED PERIOD OF REPORT: 20180930 FILED AS OF DATE: 20181114 DATE AS OF CHANGE: 20181114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cavitation Technologies, Inc. CENTRAL INDEX KEY: 0001376793 STANDARD INDUSTRIAL CLASSIFICATION: AGRICULTURE SERVICES [0700] IRS NUMBER: 204907818 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-53239 FILM NUMBER: 181182482 BUSINESS ADDRESS: STREET 1: 10019 CANOGA AVENUE CITY: CHATSWORTH, STATE: CA ZIP: 91311 BUSINESS PHONE: 818-718-0905 MAIL ADDRESS: STREET 1: 10019 CANOGA AVENUE CITY: CHATSWORTH, STATE: CA ZIP: 91311 FORMER COMPANY: FORMER CONFORMED NAME: Bioenergy Inc. DATE OF NAME CHANGE: 20060927 10-Q 1 tv507110_10q.htm FORM 10-Q

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

 

  

FORM 10-Q

 

 

  

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2018

 

Commission File Number: 0-29901

 

 

Cavitation Technologies, Inc.
(Exact name of Registrant as Specified in its Charter)

 

Nevada

20-4907818
(State or Other Jurisdiction of Incorporation or Organization)  (I.R.S. Employer Identification Number)

 

10019 CANOGA AVENUE, CHATSWORTH, CALIFORNIA    91311
(Address, including Zip Code, of Principal Executive Offices)

 

(818) 718-0905
(Registrant's Telephone Number, Including Area Code)

 

 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file reports), and (2) has been subject to such filing requirements for the past 90 days. YES    x        NO    ¨

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). YES  x     NO  ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer ¨ Accelerated filer ¨
Non–Accelerated filer  x Small reporting company x
    Emerging growth company  ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

  

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES    ¨        NO    x

 

As of November 12, 2018, the issuer had 196,997,906 shares of common stock outstanding.

 

 

   

 

 

TABLE OF CONTENTS

 

      Page
PART I.   FINANCIAL INFORMATION 3
       
Item 1.   Condensed Consolidated Financial Statements (unaudited) 3
       
    Condensed Consolidated Balance Sheets 3
       
    Condensed Consolidated Statements of Operations 4
       
    Condensed Consolidated Statement of Stockholders' Deficit 5
       
    Condensed Consolidated Statements of Cash Flows 6
       
    Notes to Condensed Consolidated Financial Statements 7
       
Item 2.   Management's Discussion and Analysis of Financial Condition and Results of Operations 13
       
Item 3.   Quantitative and Qualitative Disclosures About Market Risk 15
       
Item 4.   Controls and Procedures 15
       
PART II   OTHER INFORMATION 16
       
Item 1.   Legal Proceedings 16
       
Item 2.   Unregistered Sales of Equity Securities and Use of Proceeds 16
       
Item 3.   Defaults Upon Senior Securities 16
       
Item 4.   (Removed and Reserved) 16
       
Item 5.   Other Information 16
       
Item 6.   Exhibits 17
       
Signatures 18
   
Certifications  

 

 2  

 

 

PART I - FINANCIAL INFORMATION

 

ITEM 1 - Condensed Consolidated Financial Statements

 

CAVITATION TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS

 

   September 30,   June 30, 
   2018   2018 
   (unaudited)     
ASSETS          
           
Current assets:          
Cash and cash equivalents  $661,000   $945,000 
Accounts receivable   55,000    - 
Inventory   29,000    34,000 
Total current assets   745,000    979,000 
           
Property and equipment, net   80,000    90,000 
Other assets   10,000    10,000 
Total assets  $835,000   $1,079,000 
           
LIABILITIES AND STOCKHOLDERS' DEFICIT          
           
Current liabilities:          
Accounts payable and accrued expenses  $295,000   $307,000 
Accrued payroll and payroll taxes due to officers   863,000    889,000 
Related party payable   1,000    1,000 
Advances from distributor, net   477,000    427,000 
Total current liabilities   1,636,000    1,624,000 
           
Commitments and contingencies          
           
Stockholders' deficit:          
Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of September 30, 2018 and June 30, 2018, respectively   -    - 
Common stock, $0.001 par value, 1,000,000,000 shares authorized, 196,797,906 shares issued and outstanding as of September 30, 2018 and June 30, 2018, respectively   196,998    196,998 
Additional paid-in capital   22,641,002    22,641,002 
Accumulated deficit   (23,639,000)   (23,383,000)
Total stockholders' deficit   (801,000)   (545,000)
Total liabilities and stockholders' deficit  $835,000   $1,079,000 

 

See accompanying notes, which are an integral part of these condensed consolidated financial statements

 

 3  

 

 

CAVITATION TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

 

   For the Three Months Ended 
   September 30, 
   2018   2017 
         
Revenue  $55,000   $340,000 
Cost of revenue   5,000    19,000 
Gross profit   50,000    321,000 
           
General and administrative expenses   304,000    460,000 
Research and development expenses   2,000    3,000 
Total operating expenses   306,000    463,000 
           
Net loss  $(256,000)  $(142,000)
           
Net loss per share,          
Basic and Diluted  $(0.00)  $(0.00)
           
Weighted average shares outstanding,          
Basic and Diluted   196,797,906    197,193,558 

 

See accompanying notes, which are an integral part of these condensed consolidated financial statements

 

 4  

 

 

CAVITATION TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT (Unaudited)
AS OF SEPTEMBER 30, 2018

 

   Series A
Preferred
   Common Stock   Additional Paid-   Accumulated     
   Shares   Amount   Shares   Amount   in Capital   Deficit   Total 
Balance at June 30, 2018   -   $-    196,797,906   $196,998   $22,641,002   $(23,383,000)  $(545,000)
                                    
Net Loss                            (256,000)   (256,000)
Balance at September 30, 2018   -   $-    196,797,906   $196,998   $22,641,002   $(23,639,000)  $(801,000)

 

See accompanying notes, which are an integral part of these condensed consolidated financial statements

  

 5  

 

 

CAVITATION TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

 

   Three Months Ended September 30, 
   2018   2017 
         
Operating activities:          
Net Loss  $(256,000)  $(142,000)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:          
Depreciation and amortization   10,000    11,000 
Common stock issued to consultants   -    16,000 
Effect of changes in:          
Accounts receivable   (55,000)   (155,000)
Inventory   5,000    19,000 
Accounts payable and accrued expenses   (38,000)   90,000 
Advances from distributor   50,000    180,000 
Net cash provided by (used in) operating activities   (284,000)   19,000 
Cash, beginning of period   945,000)   549,000 
Cash, end of period  $661,000   $568,000 
           
Supplemental disclosures of cash flow information:          
Cash paid for interest  $-   $- 
Cash paid for income taxes  $-   $1,600 

 

See accompanying notes, which are an integral part of these condensed consolidated financial statements

 

 6  

 

 

CAVITATION TECHNOLOGIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
Three months ended September 30, 2018 and 2017

 

Note 1 - Organization and Summary of Significant Accounting Policies

 

Cavitation Technologies, Inc. (referred to herein, unless otherwise indicated, as "the Company," "CTi," "we," "us," and "our") is a Nevada corporation originally incorporated under the name Bio Energy, Inc. CTi has developed, patented, and commercialized proprietary technology that may be used in liquid processing applications. CTi's patented Nano Reactor® is the critical component of CTi Nano Neutralization® System which is commercially proven to reduce operating costs and increase yields in refining vegetable oils. CTi has two patented systems and has filed several national and international patents to employ its proprietary technology in applications including, vegetable oil refining, wastewater treatment, biodiesel, algae oil extraction, and alcoholic beverage enhancement.

 

Basis of Presentation

 

The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles ("GAAP") as promulgated in the United States of America ("U.S.") and with instructions to Form 10-Q pursuant to the rules and regulations of Securities and Exchange Act of 1934, as amended (the "Exchange Act") and Article 8-03 of Regulation S-X under the Exchange Act. Accordingly, these condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, we have included all adjustments considered necessary (consisting of normal recurring adjustments) for a fair presentation. Operating results for the three months ended September 30, 2018 are not indicative of the results that may be expected for the fiscal year ending June 30, 2019. You should read these unaudited condensed consolidated financial statements in conjunction with the audited financial statements and the notes thereto included in the Company's annual report on Form 10-K for the year ended June 30, 2018 filed on October 15, 2018. The condensed consolidated balance sheet as of June 30, 2018 has been derived from the audited financial statements included in the Form 10-K for that year.

 

Going Concern

 

The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. During the three months ended September 30, 2018, the Company incurred a net loss of $256,000 and used cash in operations of $284,000, and at September 30, 2018, had a working capital deficiency of $891,000 and a stockholders' deficit of $801,000.  These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued. In addition, the Company’s independent registered public accounting firm, in its report on the Company’s June 30, 2018 financial statements, has expressed substantial doubt about the Company’s ability to continue as a going concern. The accompanying condensed consolidated financial statements do not include adjustments that may result from an inability of the Company to continue as a going concern.

 

As of September 30, 2018, we had cash and cash equivalents on hand of $661,000 and are not generating sufficient revenues to fund operations. In addition to the funds on hand, management believes we may require additional funds to continue to operate our business. Management's plan is to generate income from operations by continuing to license our technology globally through our strategic partners, Desmet Ballestra Group (Desmet), GEA Westfalia, AG (GEA), and recent agreements with Alchemy Beverages, Inc.(ABI). Desmet has provided us monthly advances of $50,000 through August 2018 that was applied against gross profit share from reactor sales pursuant to a January 2016 agreement. Our agreement with Desmet expired on October 1, 2018, however, Desmet and CTi are actively pursuing to finalize a new three year term. We believe that a new license agreement with Desmet should be finalized during fiscal 2019. GEA has agreed to provide us monthly advances of $25,000 less applicable taxes through January 2020, to be applied against gross profit share from future sales pursuant to January 2017 agreement. In June 2018, we entered into two licensing agreements with ABI and anticipate to start receiving certain royalties payments and revenue stream from ABI in fiscal 2019.

 

We may also attempt to raise additional debt and/or equity financing to fund operations and provide additional working capital. However, there is no assurance that such financing will be consummated or obtained in sufficient amounts necessary to meet the Company's needs, that the Company will be able to achieve profitable operations or that the Company will be able to meet its future contractual obligations. Should management fail to obtain such financing, the Company may curtail its operations.

 

 7  

 

 

Principles of Consolidation

 

The condensed consolidated financial statements include the accounts of Cavitation Technologies, Inc. and its wholly owned subsidiary Hydrodynamic Technology, Inc. Inter-company transactions and balances have been eliminated in consolidation.

 

Fair Value Measurement

 

FASB Accounting Standards Codification ("ASC") 820-10 requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties.

 

The three levels of the fair value hierarchy are as follows:

 

·Level 1 - Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability to access.
·Level 2 - Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.
·Level 3 - Valuations based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

 

On September 30, 2018 and June 30, 2018, the fair values of cash and cash equivalents, accounts receivable, inventory and accounts payable and accrued expenses approximate their carrying values due to their short-term nature.

 

Use of Estimates

 

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date and reported amounts of revenue and expenses during the reporting period. Significant estimates are used in reserve for inventory obsolescence, impairment analysis for fixed assets, accrual of potential liabilities, deferred tax assets and valuing our stock options, warrants, and common stock issued for services, among other items. Actual results could differ from these estimates.

 

Revenue Recognition

 

Revenues from sale of reactors and the corresponding share in gross profit is recognized in accordance with ASC 606, Revenue from Contracts with Customers and all the related amendments (“new revenue standard”) to all contracts. Sales revenue from the sale of our Nano Reactors is recognized when products are shipped from our manufacturing facilities as this is our sole performance obligation under these contracts and we have no continuing obligation to the customer. Accordingly, the Company estimates and recognizes the corresponding gross profit at the time of shipment of the Nano reactor hardware, subject to variable consideration constraints, in accordance to ASC 606.

 

Specifically, the Company has determined that the gross profit to be earned from its distributor as a variable consideration that requires estimation in determining the transaction price, and as such all or a portion can be recognized using the most likely amount approach (subject to the variable consideration constraint). Estimates are available from our distributor which are considered in the determination of the most likely amount. However, given the lack of control over the sale to the end customer and the lack of history of prior sales, the Company considered these as a variable revenue constraint that required consideration and as such, the amount of revenue recognized is being limited to the actual amount of cash received under the contract which the Company has determined as not refundable and has concluded that future revenue reversal of such amount is not probable.

 

Share-Based Compensation

 

The Company periodically issues stock options and warrants to employees and non-employees in non-capital raising transactions for services and for financing costs. The Company accounts for stock option and warrant grants issued and vesting to employees based on the authoritative guidance provided by the Financial Accounting Standards Board whereas the value of the award is measured on the date of grant and recognized over the vesting period. The Company accounts for stock option and warrant grants issued and vesting to non- employees in accordance with the authoritative guidance of the Financial Accounting Standards Board whereas the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, option grants are immediately vested, and the total stock-based compensation charge is recorded in the period of the measurement date.

 

 8  

 

 

The fair value of the Company's common stock options and warrants grant is estimated using the Black-Scholes option pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the common stock options, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes option pricing model and based on actual experience. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future periods.

 

Earnings( Loss) Per Share

 

The Company’s computation of earnings (loss) per share (EPS) includes basic and diluted EPS. Basic EPS is calculated by dividing the Company’s net income (loss) available to common stockholders by the weighted average number of common shares during the period. Shares of restricted stock subject to vesting are included in basic weighted average common shares outstanding from the time they vest. Diluted EPS reflects the potential dilution, using the treasury stock method that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the net income (loss) of the Company. In computing diluted EPS, the treasury stock method assumes that outstanding options and warrants are exercised, and the proceeds are used to purchase common stock at the average market price and there were no instruments that would result in issuance of additional shares during the period.  

 

As of September 30, 2018, the Company had 11,000,000 stock options and 75,926,510 stock warrants outstanding to purchase shares of common stock that were not included in the diluted net loss per common share because their effect would be anti-dilutive.

 

Recent Accounting Pronouncements

 

In February 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-02, Leases. ASU 2016-02 requires a lessee to record a right of use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. ASU 2016-02 is effective for all interim and annual reporting periods beginning after December 15, 2018. Early adoption is permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. In July 2018, the FASB issued ASU 2018-11, Targeted Improvements, which allows for a cumulative-effect adjustment in the period the new lease standard is adopted and will not require restatement of prior periods. The Company is in the process of evaluating the impact of ASU 2016-02 and ASU 2018-11 on the Company’s financial statements and disclosures.

 

In January 2016, the FASB issued ASU 2016-01, Financial Instruments (Subtopic 825-10) - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities. ASU 2016-01 provides guidance on how entities measure certain equity investments and present changes in the fair value. This standard requires that entities measure certain equity investments that do not result in consolidation and are not accounted for under the equity method at fair value and recognize any changes in fair value in net income. ASU 2016-01 is effective for fiscal years beginning after December 31, 2017. The Company adopted the guidance of ASU No. 2016-01 on July 1, 2018 and there was no effect to the Company’s consolidated financial statements.

 

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company's present or future consolidated financial statements.

 

Note 2 - Agreement with Distributors

 

Desmet Ballestra Agreement

 

On January 22, 2016, the Company signed a three-year agreement with Desmet for the sale and marketing of the Company’s Nano reactor system. As part of the agreement, Desmet provided, under certain conditions, limited monthly advance payments of $50,000 against future gross profit share to CTi through August 2018. The agreement expired on October 1, 2018 and Desmet and CTi are working on a new three year licensing agreement which we estimated will be finalized during fiscal 2019.

 

 9  

 

 

The Company recognizes revenue from sale of reactors upon shipment and acceptance by Desmet, as the Company has no further obligations to Desmet other than the reactor’s two-year standard warranty. In addition, Desmet pays for such reactors on credit terms and the amount of the sale is recorded as a receivable upon acceptance by Desmet. The Company also receives a share in gross margin or profit from the sale of Desmet’s integrated neutralization system to its customer of which the reactors are an integral component, however, such amount is subject to adjustment based on certain factors including costs over run. The Company recognizes the gross profit at the time of shipment of the Nano reactor hardware in accordance to ASC 606 as such shipment is deemed to be the only performance obligation and the Company has no more continuing obligation to Desmet. In addition, the Company has no control with regards to the sale and installation of Nano Neutralization System, between our distributor and the end customer. The Company has determined that the gross profit to be earned from Desmet as a variable consideration that requires estimation in determining the transaction price, and as such all or a portion can be recognized using the most likely amount approach (subject to the variable consideration constraint). Estimates are available from Desmet which are considered in the determination of the most likely amount. However, given the lack of control over the sale to the end customer and the lack of history of prior sales, the Company considered these as a variable revenue constraint that required consideration. Thus, the amount of revenue recognized is being limited to the actual amount of cash received under the contract which the Company has determined as not refundable and preclude any probable of future revenue reversal. Further, Company has been able to develop an expectation of the actual collection based on its historical experience.

 

During the three months ended September 30, 2018 and 2017, the Company recognized revenue of $55,000 and $340,000, respectively, related to the shipment and acceptance of reactors to Desmet.

 

GEA Westfalia Agreement

 

In January 2017 we entered into a global technology license, R&D and marketing agreement with respect to our patented Nano Reactor™ technology, processes and applications. Under the agreement, GEA has been granted a worldwide exclusive license to integrate our patented technology into water treatment application, milk and juice pasteurization, and certain food related processes. The license agreement between us and GEA has a three-year term and provides for the payment of $300,000 per year in advanced license fees or share in gross margin or profit to us.

 

Revenues from sale of reactors and share in gross profit is being recognized in accordance with current accounting guidelines as previously discussed in the Desmet Ballestra Agreement.

 

As of June 30, 2018, outstanding advances from GEA to be applied to share in gross profit in future period amounted to $427,000. During the period ended September 30, 2018, we received additional advances totaling $50,000 from GEA. As of September 30, 2018, outstanding advance from GEA amounted to $477,000.

 

There were no reactor sales or gross profit or margin revenue recognized during the period ended September 30, 2018.

 

Alchemy Beverages, Inc. Agreement

 

In June 2018, the Company entered into licensing agreements with Alchemy Beverages Inc. (ABI). Pursuant to the licensing agreements, ABI has the exclusive global distribution rights for the Company’s patented and patent pending technology for the processing of alcoholic beverages. The Company has agreed to assist in the installation and maintenance of the nano reactor systems for ABI and will receive royalty payments ranging from 1% to 3% on all net revenues, as defined, of ABI for the life of the applicable patents. In addition, the Company will receive leasing, consulting, and manufacturing fees as defined. In addition, on a future transaction involving the sale of ABI, the Company will receive approximately 10% of the transaction price (with a minimum of $5 million) and in the event ABI becomes a public entity, the Company will receive approximately 10% of ABI’s shares. There was no revenue recognized during the period ended September 30, 2018 pursuant to these agreements.

 

At September 30, 2018, the Company owns 19.9% of ABI. The investment in ABI has no value assigned to it, which approximates its fair value.

 

 10  

 

 

Note 3 - Stockholders' Deficit

 

Stock Options

 

The Company has not adopted a formal stock option plan. However, it has assumed outstanding stock options resulting from the acquisition of its wholly-owned subsidiary, Hydrodynamic Technology, Inc. In addition, the Company has made periodic non- plan grants. A summary of the stock option activity during the three months ended September 30, 2018 is as follows:

 

           Weighted- 
           Average 
       Weighted-   Remaining 
       Average   Contractual 
       Exercise   Life 
   Options   Price   (Years) 
             
Outstanding at June 30, 2018   11,378,754   $0.31    2.23 
- Granted   -    -    - 
- Forfeited   (378,754)   -    - 
- Exercised   -    -    - 
- Expired   -    -    - 
Outstanding at September 30, 2018   11,000,000   $0.03    2.00 
Exercisable and vested at September 30, 2018   11,000,000   $0.03    2.00 

 

As of September 30, 2018, all outstanding options are fully vested. There was no intrinsic value of the outstanding options as of September 30, 2018 as the exercise price of these options were greater than the market price. The following table summarizes additional information concerning options outstanding and exercisable at September 30, 2018.

 

    Options Outstanding   Options Exercisable 
        Weighted   Weighted       Weighted 
        Average   Average       Average 
Exercise   Number   Remaining   Exercise   Number   Remaining 
Price   of Shares   Life (Years)   Price   of Shares   Life (Years) 
                            
$0.03    11,000,000    2.00   $0.03    11,000,000    2.00 

 

Warrants

 

A summary of the Company's warrant activity and related information for the three months ended on September 30, 2018 is as follows.

 

                Weighted-  
                Average  
          Weighted-     Remaining  
          Average     Contractual  
          Exercise     Life  
Warrants         Price     (Years)  
                   
Outstanding at June 30, 2018     75,926,510     $ 0.06       3.81  
Granted     -       -       -  
Exercised     -                  
Expired     -                  
Outstanding at September 30, 2018     75,926,510       0.06       3.56  
Vested and exercisable at September 30, 2018     75,926,510     $ 0.06       3.56  

 

 11  

 

 

As of September 30, 2018, all outstanding warrants are fully vested. There was no intrinsic value of the outstanding warrants as of September 30, 2018 as the exercise price of these warrants were greater than the market price. The following table summarizes additional information concerning warrants outstanding and exercisable at September 30, 2018.

 

   Warrants Outstanding   Warrants Exercisable 
       Weighted   Weighted       Weighted 
       Average   Average       Average 
Exercise  Number   Remaining   Exercise   Number   Exercise 
Price  of Shares   Life (Years)   Price   of Shares   Price 
                     
$0.03 - 0.07   55,599,851    6.50   $0.05    55,599,851   $0.05 
$0.12   20,326,659    3.00   $0.12    20,326,659   $0.12 
    75,926,510              75,926,510      

 

Note 4 - Commitments and Contingencies

 

Royalty Agreements

 

On July 1, 2008, our wholly owned subsidiary entered into Patent Assignment Agreements with two parties, our President and Technology Development Supervisor, where certain devices and methods involved in the hydrodynamic cavitation processes invented by the President and the Technology Development Supervisor have been assigned to the Subsidiary.  In exchange, the Subsidiary agreed to pay a royalty of 5% of gross revenues to each of the President and Technology Development Supervisor for licensing of the technology and leasing of the related equipment embodying the technology. These agreements were subsequently assumed by Cavitation Technologies on May 13, 2010 from its subsidiary. The Company's President and Global Technology Manager both waived their rights to receive royalty payments that have accrued, or that may accrue, on any gross revenue generated through September 30, 2018.

 

On April 30, 2008 and as amended on November 22, 2010, our wholly owned subsidiary entered into an employment agreement with our former Director of Chemical and Analytical Department (the "Inventor") to receive an amount equal to 5% of actual gross royalties received from the royalty stream in the first year in which the Company receives royalty payments from the patent which the Inventor was the legally named inventor, and 3% of actual gross royalties received by the Company resulting from the patent in each subsequent year. As of September 30, 2018, no patents have been granted in which this person is the legally named inventor.

 

 12  

 

 

ITEM 2.  Management's Discussion and Analysis of Financial Condition and Results of Operations.

 

The following discussion and analysis should be read in conjunction with our financial statements and the related notes. This discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties, such as its plans, objectives, expectations and intentions. Its actual results and the timing of certain events could differ materially from those anticipated in these forward-looking statements.

 

Overview of our Business

 

Cavitation Technologies, Inc. ("CTi"), a Nevada corporation, was originally incorporated under the name Bio Energy, Inc. We design and engineer environmentally friendly technology-based systems that are designed to serve large, growing, global markets such as vegetable oil refining, renewable fuels, water treatment, algae oil extraction, biodiesel production, water-oil emulsions and crude oil yield enhancement.  Our systems are designed to process industrial liquids at a lower cost and higher yield than conventional technology. We are a process and product development firm that has developed, patented, and commercialized proprietary technology.

 

CTi has developed, patented, and commercialized proprietary technology that can be used for processing of industrial fluids. CTi's patented Nano Reactor® is the critical components of the CTi Nano Neutralization® System which is commercially proven to reduce operating costs and increase yields in processing oils and fats. CTi has two issued patents relating to our Nano Reactor® systems and has filed several national and international patents to employ its proprietary technology in applications including, vegetable oil refining, biodiesel production, waste water treatment, algae oil extraction, and alcoholic beverage enhancement.

 

During the three months ended September 30, 2018, we recorded revenue of $55,000 and incurred a net loss of $256,000.

 

Management's Plan

 

We are engaged in manufacturing our Neutralization System, which is designed to help refine vegetable oils such as soybean, canola, sunflower and rapeseed.  Our near-term goal is to continue to sell our systems through our partners, Desmet Ballestra and GEA. During the three months ended September 30, 2018, we recorded revenues of $55,000 and incurred a net loss of $256,000.  As of September 30, 2018, the Company had a working capital deficiency of $891,000 and a stockholders' deficit of $801,000. The accompanying financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern.

 

As of September 30, 2018, we had cash and cash equivalents on hand of $661,000 and are not generating sufficient revenues to fund operations. In addition to the funds on hand, Management believes we may require additional funds to continue to operate our business. Management's plan is to generate income from operations by continuing to market our technology and products globally through our strategic partner, Desmet Ballestra and GEA Group. Further, we believe our business development with Alchemy Beverages, Inc may start generating revenues in our Fiscal 2019.

 

Desmet had provided monthly advances of $50,000 while GEA is providing monthly advances of $25,000, however, we anticipate that we may need additional funding, and we may attempt to raise additional debt and/or equity financing to fund operations and to provide additional working capital. However, there is no assurance that we will be successful in obtaining such financing will be or obtained sufficient amounts necessary to meet our business needs, or that we will be able to meet our future contractual obligations.

 

Critical Accounting Policies

 

Revenue Recognition

 

Revenues from sale of reactors and the corresponding share in gross profit is recognized in accordance with ASC 606, Revenue from Contracts with Customers and all the related amendments (“new revenue standard”) to all contracts. Sales revenue from the sale of our Nano Reactors is recognized when products are shipped from our manufacturing facilities as this is our sole performance obligation under these contracts and we have no continuing obligation to the customer. Accordingly, the Company estimates and recognizes the corresponding gross profit at the time of shipment of the Nano reactor hardware, subject to variable consideration constraints, in accordance to ASC 606.

 

Specifically, the Company has determined that the gross profit to be earned from its distributor as a variable consideration that requires estimation in determining the transaction price, and as such all or a portion can be recognized using the most likely amount approach (subject to the variable consideration constraint). Estimates are available from our distributor which are considered in the determination of the most likely amount. However, given the lack of control over the sale to the end customer and the lack of history of prior sales, the Company considered these as a variable revenue constraint that required consideration and as such, the amount of revenue recognized is being limited to the actual amount of cash received under the contract which the Company has determined as not refundable and has concluded that future revenue reversal of such amount is not probable.

 

 13  

 

 

Share-Based Compensation

 

The Company periodically issues stock options and warrants to employees and non-employees in non-capital raising transactions for services and for financing costs. The Company accounts for stock option and warrant grants issued and vesting to employees based on the authoritative guidance provided by the Financial Accounting Standards Board whereas the value of the award is measured on the date of grant and recognized over the vesting period. The Company accounts for stock option and warrant grants issued and vesting to non- employees in accordance with the authoritative guidance of the Financial Accounting Standards Board whereas the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, option grants are immediately vested, and the total stock-based compensation charge is recorded in the period of the measurement date.

 

The fair value of the Company's common stock options and warrants grant is estimated using the Black-Scholes option pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the common stock options, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes option pricing model and based on actual experience. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future periods.

 

Recently Issued Accounting Standards

 

See Note 1 of the Condensed Consolidated Financial Statements for a discussion of recently issued accounting standards.

 

Results of Operations

 

Results of Operations for the Three Months Ended September 30, 2018 and 2017

 

   For the Three Months Ended         
   September 30,         
   2018   2017   $ Change   % Change 
                 
Revenue  $55,000   $340,000   $(285,000)   (84)%
Cost of revenue   5,000    19,000    (14,000)   (74)%
Gross profit   50,000    321,000    (271,000)   (84)%
                     
General and administrative expenses   304,000    460,000    (156,000)   (34)%
Research and development expenses   2,000    3,000    1,000    (33)%
Total operating expenses   306,000    463,000    (157,000)   (34)%
Net loss  $(256,000)  $(142,000)   114,000    80%

 

Revenue

 

The Company generates revenues from the sale of the Nano Reactor® to customers/distributor as well as share in gross profit from the sale of such reactors by our distributors to their customers.

 

During the three months ended September 30, 2018, the Company recognized revenues of $55,000 from sale of reactors to Desmet pursuant to one purchase order. There was no revenues recognized attributable from our share in gross profit.

 

During the three months ended September 30, 2017, the Company recognized revenues of $240,000 from sale of reactors to Desmet pursuant to two purchase orders. In addition, the Company also recognized the corresponding gross profit of $100,000.

 

Cost of Revenue

 

During the three months ended September 30, 2018, our cost of sales amounted to $5,000, and to $19,000 during the same period in prior year, which was the result of the revenue transactions described above.

 

 14  

 

 

Operating Expenses

 

Operating expenses for the three months ended September 30, 2018 amounted to $306,000 compared with $463,000 for the same period in 2017, a decrease of $157,000, or 34%. The decrease in operating expenses was due to decrease in legal expenses as a result of a settlement of litigation with a former employee in March 2018. In addition, other professional fees also decreased due to decrease in the services rendered.

 

Research and development (R&D) expenses remained relatively low as we continued to rely on Desmet and GEA for support in R&D and development of new applications for our technology. It is our intention to pursue R&D as our cash position permits.

 

Liquidity and Capital Resources

 

During the three months ended September 30, 2018, the Company incurred a net loss of $256,000 and used cash in operations of $284,000, and at September 30, 2018, had a working capital deficiency of $891,000 and a stockholders' deficit of $801,000. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued. In addition, the Company’s independent registered public accounting firm, in its report on the Company’s June 30, 2018 financial statements, has expressed substantial doubt about the Company’s ability to continue as a going concern.

 

As of September 30, 2018, we had cash and cash equivalents on hand of $661,000 and are not generating sufficient revenues to fund operations. In addition to the funds on hand, management believes we may require additional funds to continue to operate our business. Management's plan is to generate income from operations by continuing to license our technology globally through our strategic partners, Desmet Ballestra Group (Desmet), GEA Westfalia, AG (GEA), and recent agreements with Alchemy Beverages, Inc.(ABI). Desmet has provided us monthly advances of $50,000 through August 2018 that was applied against gross profit share from reactor sales pursuant to a January 2016 agreement. Our agreement with Desmet expired on October 1, 2018, however, Desmet and CTi are actively pursuing to finalize a new three-year term. We believe that a new license agreement with Desmet should be finalized during fiscal 2019. GEA has agreed to provide us monthly advances of $25,000 less applicable taxes through January 2020, to be applied against gross profit share from future sales pursuant to January 2017 agreement. In June 2018, we entered into two licensing agreements with ABI and anticipate to start receiving certain royalties payments and revenue stream from ABI in fiscal 2019.

 

We may also attempt to raise additional debt and/or equity financing to fund operations and provide additional working capital. However, there is no assurance that such financing will be consummated or obtained in sufficient amounts necessary to meet the Company's needs, that the Company will be able to achieve profitable operations or that the Company will be able to meet its future contractual obligations. Should management fail to obtain such financing, the Company may curtail its operations.

 

ITEM 3.  Quantitative and Qualitative Disclosures about Market Risk.

 

Not applicable for smaller reporting companies.

 

ITEM 4.  Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

In accordance with rule 13a-15(a), CTi management must maintain disclosure controls and procedures as defined in Rule 13a-15(e) of the Securities and Exchange Act of 1934, or the Exchange Act, to provide reasonable assurance that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms, and accumulated and communicated to the Company's management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

 

In accordance with Rule 13a-15(b) and (c), management must also evaluate the effectiveness of these disclosure control and procedures at the end of each fiscal year. As of September 30, 2018, the Company carried out an evaluation, under the supervision and with the participation of its principal executive officer and principal financial officer, of the effectiveness of the design and operation of the Company's disclosure controls and procedures. Based upon that evaluation, the Company's principal executive officer and principal financial officer concluded that these disclosure controls and procedures were not effective as of September 30, 2018.

 

 15  

 

 

Changes in Internal Control over Financial Reporting

 

There were additional controls implemented in internal control over financial reporting during the first quarter of fiscal 2019.

 

PART II - OTHER INFORMATION

 

Item 1  Legal Proceedings

 

We know of no material, existing or pending legal proceeding against our Company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our interest.

 

Item 2  Unregistered Sales of Equity Securities and Use of Proceeds

 

None

 

Item 3 - Defaults Upon Senior Securities

 

None

 

Item 4 - Mine Safety Disclosures

 

None

 

Item 5 - Other Information

 

None

 

 16  

 

 

Item 6 - EXHIBITS, FINANCIAL STATEMENT SCHEDULES

 

      Incorporated by Reference
Exhibit   Filed        
Number Exhibit Description Herewith Form Pd. Ending Exhibit Filing Date
             
3(i)(a) Articles of Incorporation - original name of Bioenergy, Inc.   SB-2 N/A 3.1 October 19, 2006
3(i)(b) Articles of Incorporation - Amended and Restated   10-Q December 31, 2008 3-1 February 17, 2009
3(i)(c) Articles of Incorporation - Amended and Restated   10-Q June 30, 2009 3-1 May 14, 2009
3(i)(d) Articles of Incorporation - Amended; increase in authorized shares   8-K N/A N/A October 29, 2009
3(i)(e) Articles of Incorporation - Certificate of Amendment; forward split   10-Q December 31, 2009 3-1 November 16, 2009
             
10.1 Patent Assignment Agreement between the Company and Roman Gordon dated July 1, 2008.   8-K June 30, 2009 10.1 May 18, 2010
10.2 Patent Assignment Agreement between the Company and Igor Gorodnitsky dated July 1, 2008.   8-K June 30, 2009 10.2 May 18, 2010
10.3 Assignment of Patent Assignment Agreement between the Company and Roman Gordon   8-K June 30, 2009 10.3 May 18, 2010
10.4 Assignment of Patent Assignment Agreement between the Company and Igor Gorodnitsky   8-K June 30, 2009 10.4 May 18, 2010
10.5 Employment Agreement between the Company and Roman Gordon date March 17, 2008   10K/A June 30, 2009 10.3 October 20, 2011
10.6 Employment Agreement between the Company and Igor Gorodnitsky dated March 17, 2008   10K/A June 30, 2009 10.4 October 20, 2011
10.7 Employment and Confidentiality and Invention Assignment Agreement between the Company and Varvara Grichko dated April 30, 2008   10-Q December 31, 2010 10.3 February 11, 2011
10.8 Board of Director Agreement - James Fuller   10-Q December 31, 2011 10.12 October 20, 2011
10.9 Technology and License Agreement with Desmet Ballestra dated 14 May 2012   10-K June 30, 2012 10.1 October 15, 2012
10.10 Short Term Loan Agreement - CEO    10-K June 30, 2012 10.11 October 15, 2012
10.11 Loan Agreement - Desmet Ballestra - Oct. 26, 2010          
             
14.1 Code of Business Conduct and Ethics*   10-K June 30, 2011 14.1 September 28, 2011
31.1 Certificate of Principal Executive Officer pursuant to Section 302 of Sarbanes-Oxley Act of 2002 X        
31.2 Certificate of Principal Financial Officer pursuant to Section 302 of Sarbanes-Oxley Act of 2002 X        
32.1 Certification of Principal Executive Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. X        
32.2 Certification of Principal Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. X        
             
101.INS XBRL Instance Document X        
101.SCH XBRLTaxonomy Extension Schema X        
101.CAL XBRL Taxonomy Extension Calculation Linkbase X        
101.DEF XBRL Taxonomy Extension Definition Linkbase X        
101.LAB XBRL Taxonomy Extension Label Linkbase X        
101.PRE XBRL Taxonomy Extension Presentation Linkbase X        
             
* In accordance with Regulation S-K 406 of the Securities Act of 1934, we undertake to provide to any person without charge, upon request, a copy of our "Code of Business Conduct and Ethics". A copy may be requested by sending an email to info@cavitationtechnologies.com.          

  

 17  

 

 

SIGNATURES

 

Pursuant to the requirements of the securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

SIGNATURE   TITLE   DATE
         
/s/ Igor Gorodnitsky   President; Member of Board of Directors   November  14, 2018
Igor Gorodnitsky   (Principal Executive Officer)    
         
/s/ N. Voloshin   Chief Financial Officer   November  14, 2018
N. Voloshin    (Principal Financial Officer)    
         
/s/ Jim Fuller

Audit Committee Chairman,

November  14, 2018
Jim Fuller Independent Financial Expert    

 

 18  

 

 

EX-31.1 2 tv507110_ex31-1.htm EXHIBIT 31.1

 

Exhibit 31.1

 

Certification

 

I, Igor Gorodnitsky, certify that:

 

1. I have reviewed this quarterly report for the period ending September 30, 2018 on Form 10-Q of Cavitation Technologies, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: November 14, 2018 /s/ IGOR GORODNITSKY
  Name: Igor Gorodnitsky
Title: Principal Executive Officer 

 

 

 

EX-31.2 3 tv507110_ex31-2.htm EXHIBIT 31.2

 

Exhibit 31.2

 

Certification

 

I, N. Voloshin, certify that:

 

1. I have reviewed this quarterly report for the period ending September 30, 2018 on Form 10-Q of Cavitation Technologies, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: November 14, 2018 /s/ N. VOLOSHIN
  Name: N. Voloshin
Title: Chief Financial Officer

 

 

EX-32.1 4 tv507110_ex32-1.htm EXHIBIT 32.1

 

Exhibit 32.1

 

CERTIFICATION

 

I, Igor Gorodnitsky, Principal Executive Officer of Cavitation Technologies, Inc. (the "Company"), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:

 

The Quarterly Report on Form 10-Q of the Company for the quarter ended September 30, 2018 (the "Report") fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and

 

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: November 14, 2018 /s/ IGOR GORODNITSKY
  Name: Igor Gorodnitsky
Title: Principal Executive Officer

 

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

  

 

 

EX-32.2 5 tv507110_ex32-2.htm EXHIBIT 32.2

  

Exhibit 32.2

 

CERTIFICATION

 

I, N. Voloshin, Chief Financial Officer of Cavitation Technologies, Inc. (the "Company"), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:

 

The Quarterly Report on Form 10-Q of the Company for the quarter ended September 30, 2018 (the "Report") fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and

 

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: November 14, 2018 /s/ N. VOLOSHIN
  Name: N. Voloshin
Title: Chief Financial Officer

 

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

 

GRAPHIC 6 tv507110_logo.jpg GRAPHIC begin 644 tv507110_logo.jpg M_]C_X 02D9)1@ ! @ 9 !D #_[ 11'5C:WD 0 $ / _^X #D%D M;V)E &3 ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! , M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8 M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\? M'Q\?'Q\?'Q\?_\ $0@ - !3 P$1 (1 0,1 ?_$ )( $$ P$ M <"!08( 0,$ $ P$! 0 @,$ $%$ ! P($ P4$ M!P8' ! @,$$04 ,1(&(1,'05%A(A1Q,A4(@=%"4B,S%J&Q M;M.O53@%&D<.TJ[,9T1RCDATZ]3)TV1->D*YLEQ3JZ M+(%5&N5<%2J)]EFGP:1,D$T$A?L"S]>#:1V7;(H2Y1XKKIS_H\,)*^MBPE[O-OL]O>N$]X,Q6$U6LGM[AX]V 52_9;JBMF_P#JK>]T M2%QXZUQ+.A5&XR#I6X/O.D?NP^M#S=GH[#%8=IR+E&7<7WV[;9&3I?N3YHBH M^RVG-:O 8X[0+6MLE$&U6>*D/6?:\B^(2*"XW1STK"O%#>=/;@'L&K29E[HW M[:K:^VSM"VMVAXA3P:;Y[:M.6I25&M,+M=@7>RF57'Y$<:ZHRUO-MC;MGU*4 ME%#'-:E5*9X!79-K]MG:'7]"7]9S8(2+7:[?;X\6:XVF3.4RV 1J2*)%/'CB MK6VRWT/[0#:VV]^XSXT",DJD27$M("NVX562*Y2WVPT= R6^?>KWA.&TJ>=Z=DD7V! ML]W=>Y6+;Q3%1^+,<^ZTG,>U66&6M C1JECM?9WQ7K QMEQ 8L%B5RH< <$! M2 "7"D<%*)/;B=N2VBK,$FFKVU^OW+7?;BE4]:$*ML!>OEMLJ%1H%-)4>TXV M"M]:K@V13:;=O2-$M16/7:V9<1!JTX@BNLHXT4GOP3B#J::E\$!.V&Y?61$! MA-(#*_62B."6FV?.HJ/9EA<$.SR*>R.#=M\=ONXYMS624N.$,5[&D>5 'T8I MUX1+Z/WJ4R<]!]OMR;[)W#* $.TMJT*5ES5#/^5-<Q%?FND1+J+#NC/4&7NVQ0WY%N4XEQ$U+:BTI M8%%BH^S49XFD3;?>EVXP=TSJ7T^W"8+^Y+9)AWBWI(9N,,@N)"LPGTVVWAZ_06E.6VI:L%$<"8M9R MV3'IE9V+CNZ+;H +C;1YT^<1FVCB4-]R5'MPNS95I3[Y%=:MRJNV[UPV5@Q+ M6D,-"M05YN?5@J5%^R[F$-73';1O^\840IK%CJ]3))X^5!K^_&V/)M-$V6Q; M2E* E(T@< .X82>IP+Q@I-3L=E]E33R$N-K&E2%"H([B#C<'+*0;[BZ$[0NK MBWX?,M;ZR2>3^57^!7^PEMYY(B_\ +A<@L\F\M%'85ME)I]!P7R,2_(9C M?+A<"H>HO+81VE#9)^BI&-\C.+R';>>DFR]G[;EWJY+=N,B,@\E#J@ALN*X( M&A/CXXXK2QC\]:J0+3;G-F?GN$('N,)&EM/\HX<._#B&]_H@P=-(S.T^G5TW M=)3ID2TE,,'@2@<$?ZE84UDKTS77+ S(=%,9G$8 M.BGA@5 1X:/IP9F>&GACAQ D^8KUWZ>@]YM%*:>W/#W]CS:Y/\ YY8?0:_@FENO*I]SRUKXX2NG M^& *_P#5:AJY^FHU5T^[VY>&'6X/.UQ]"WVU/AGZ EX-101.INS 7 cvat-20180930.xml XBRL INSTANCE DOCUMENT 0001376793 2018-06-30 0001376793 2017-06-30 0001376793 CVAT:GEAWestfaliaMember 2018-06-30 0001376793 us-gaap:StockOptionMember 2017-07-01 2018-06-30 0001376793 us-gaap:StockOptionMember 2017-06-30 0001376793 us-gaap:StockOptionMember 2018-06-30 0001376793 CVAT:Price1Member 2018-06-30 0001376793 us-gaap:WarrantMember 2017-07-01 2018-06-30 0001376793 us-gaap:WarrantMember 2017-06-30 0001376793 us-gaap:WarrantMember 2018-06-30 0001376793 CVAT:WarrantPrice1Member 2018-07-01 2018-09-30 0001376793 CVAT:WarrantPrice2Member 2018-07-01 2018-09-30 0001376793 CVAT:WarrantPrice1Member 2018-09-30 0001376793 CVAT:WarrantPrice2Member 2018-09-30 0001376793 2018-07-01 2018-09-30 0001376793 2018-11-12 0001376793 2018-09-30 0001376793 2017-07-01 2017-09-30 0001376793 us-gaap:PreferredStockMember 2018-06-30 0001376793 us-gaap:PreferredStockMember 2018-09-30 0001376793 2017-09-30 0001376793 us-gaap:StockOptionMember 2018-07-01 2018-09-30 0001376793 us-gaap:WarrantMember 2018-07-01 2018-09-30 0001376793 CVAT:DesmetBallestraMember 2018-07-01 2018-09-30 0001376793 CVAT:DesmetBallestraMember 2017-07-01 2017-09-30 0001376793 CVAT:GEAWestfaliaMember 2018-09-30 0001376793 CVAT:GEAWestfaliaMember 2018-07-01 2018-09-30 0001376793 CVAT:AlchemyMember 2018-07-01 2018-09-30 0001376793 us-gaap:StockOptionMember 2018-07-01 2018-09-30 0001376793 us-gaap:StockOptionMember 2018-09-30 0001376793 CVAT:Price1Member 2018-07-01 2018-09-30 0001376793 CVAT:Price1Member 2018-09-30 0001376793 us-gaap:WarrantMember 2018-07-01 2018-09-30 0001376793 us-gaap:WarrantMember 2018-09-30 0001376793 us-gaap:RetainedEarningsMember 2018-07-01 2018-09-30 0001376793 us-gaap:CommonStockMember 2018-06-30 0001376793 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001376793 us-gaap:RetainedEarningsMember 2018-06-30 0001376793 us-gaap:CommonStockMember 2018-09-30 0001376793 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0001376793 us-gaap:RetainedEarningsMember 2018-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares CVAT:Integer xbrli:pure 196997906 945000 549000 661000 568000 0 55000 34000 29000 979000 745000 90000 80000 10000 10000 1079000 835000 307000 295000 889000 863000 1000 1000 427000 427000 477000 477000 1624000 1636000 0 0 196998 196998 22641002 22641002 -23383000 -23639000 -545000 -801000 0 0 196998 22641002 -23383000 196998 22641002 -23639000 1079000 835000 0.001 0.001 10000000 10000000 0 0 0 0 0.001 0.001 1000000000 1000000000 196997906 196997906 196997906 196997906 55000 340000 55000 340000 0 -256000 -142000 -256000 -0.00 -0.00 11685852 11378754 11000000 11000000 0 0 0 378754 0 0 307098 0 0.37 0.31 0.03 0.03 P2Y2M23D P2Y P2Y 11378754 11000000 11000000 P2Y 75926510 75926510 55599851 20326659 75926510 0 0 0 0.06 0.06 0.05 0.12 0.06 P3Y9M22D P6Y6M P3Y P3Y6M22D 55599851 20326659 75926510 0.05 0.12 0.06 Cavitation Technologies, Inc. 0001376793 10-Q 2018-09-30 false --06-30 Yes Non-accelerated Filer false true Q1 2019 5000 19000 50000 321000 304000 460000 2000 3000 306000 463000 196797906 197193558 0 0 196797906 196797906 10000 11000 0 16000 55000 155000 -5000 -19000 -38000 90000 50000 180000 50000 -284000 19000 0 0 0 1600 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 8pt"></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt"><b>Note 1 - Organization and Summary of Significant Accounting Policies</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">Cavitation Technologies, Inc. (referred to herein, unless otherwise indicated, as &#34;the Company,&#34; &#34;CTi,&#34; &#34;we,&#34; &#34;us,&#34; and &#34;our&#34;) is a Nevada corporation originally incorporated under the name Bio Energy, Inc. CTi has developed, patented, and commercialized proprietary technology that may be used in liquid processing applications. CTi's patented <i>Nano Reactor&#174;</i> is the critical component of CTi <i>Nano Neutralization&#174; System</i> which is commercially proven to reduce operating costs and increase yields in refining vegetable oils. CTi has two patented systems and has filed several national and international patents to employ its proprietary technology in applications including, vegetable oil refining, wastewater treatment, biodiesel, algae oil extraction, and alcoholic beverage enhancement.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt"><u>Basis of Presentation</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles (&#34;GAAP&#34;) as promulgated in the United States of America (&#34;U.S.&#34;) and with instructions to Form 10-Q pursuant to the rules and regulations of Securities and Exchange Act of 1934, as amended (the &#34;Exchange Act&#34;) and Article 8-03 of Regulation S-X under the Exchange Act. Accordingly, these condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, we have included all adjustments considered necessary (consisting of normal recurring adjustments) for a fair presentation. Operating results for the three months ended September 30, 2018 are not indicative of the results that may be expected for the fiscal year ending June 30, 2019. You should read these unaudited condensed consolidated financial statements in conjunction with the audited financial statements and the notes thereto included in the Company's annual report on Form 10-K for the year ended June 30, 2018 filed on October 15, 2018. The condensed consolidated balance sheet as of June 30, 2018 has been derived from the audited financial statements included in the Form 10-K for that year.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt"><u>Going Concern</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. During the three months ended September 30, 2018, the Company incurred a net loss of $256,000 and used cash in operations of $284,000, and at September 30, 2018, had a working capital deficiency of $891,000 and a stockholders' deficit of $801,000.&#160;&#160;These factors, among others, raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year of the date that the financial statements are issued. In addition, the Company&#8217;s independent registered public accounting firm, in its report on the Company&#8217;s June 30, 2018 financial statements, has expressed substantial doubt about the Company&#8217;s ability to continue as a going concern. The accompanying condensed consolidated financial statements do not include adjustments that may result from an inability of the Company to continue as a going concern.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">As of September 30, 2018, we had cash and cash equivalents on hand of $661,000 and are not generating sufficient revenues to fund operations. In addition to the funds on hand, management believes we may require additional funds to continue to operate our business. Management's plan is to generate income from operations by continuing to license our technology globally through our strategic partners, Desmet Ballestra Group (Desmet), GEA Westfalia, AG (GEA), and recent agreements with Alchemy Beverages, Inc.(ABI). Desmet has provided us monthly advances of $50,000 through August 2018 that was applied against gross profit share from reactor sales pursuant to a January 2016 agreement. Our agreement with Desmet expired on October 1, 2018, however, Desmet and CTi are actively pursuing to finalize a new three year term. We believe that a new license agreement with Desmet should be finalized during fiscal 2019. GEA has agreed to provide us monthly advances of $25,000 less applicable taxes through January 2020, to be applied against gross profit share from future sales pursuant to January 2017 agreement. In June 2018, we entered into two licensing agreements with ABI and anticipate to start receiving certain royalties payments and revenue stream from ABI in fiscal 2019.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">We may also attempt to raise additional debt and/or equity financing to fund operations and provide additional working capital. However, there is no assurance that such financing will be consummated or obtained in sufficient amounts necessary to meet the Company's needs, that the Company will be able to achieve profitable operations or that the Company will be able to meet its future contractual obligations. Should management fail to obtain such financing, the Company may curtail its operations.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt"></font>&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt"><b><i>Principles of Consolidation</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt"><b><i>&#160;</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">The condensed consolidated financial statements include the accounts of Cavitation Technologies, Inc. and its wholly owned subsidiary Hydrodynamic Technology, Inc. Inter-company transactions and balances have been eliminated in consolidation.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt"><b><i>Fair Value Measurement</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt"><b><i>&#160;</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">FASB Accounting Standards Codification (&#34;ASC&#34;) 820-10 requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">The three levels of the fair value hierarchy are as follows:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font: 8pt Symbol">&#183;</font></td><td style="text-align: justify"><font style="font-size: 8pt">Level 1 - Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability to access.</font></td></tr></table> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font: 8pt Symbol">&#183;</font></td><td style="text-align: justify"><font style="font-size: 8pt">Level 2 - Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.</font></td></tr></table> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font: 8pt Symbol">&#183;</font></td><td style="text-align: justify"><font style="font-size: 8pt">Level 3 - Valuations based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</font></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">On September 30, 2018 and June 30, 2018, the fair values of cash and cash equivalents, accounts receivable, inventory and accounts payable and accrued expenses approximate their carrying values due to their short-term nature.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt"><b><i>Use of Estimates</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt"><b><i>&#160;</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date and reported amounts of revenue and expenses during the reporting period. Significant estimates are used in reserve for inventory obsolescence, impairment analysis for fixed assets, accrual of potential liabilities, deferred tax assets and valuing our stock options, warrants, and common stock issued for services, among other items. Actual results could differ from these estimates.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt"><b><i>&#160;</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt"><b><i>Revenue Recognition</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">Revenues from sale of reactors and the corresponding share in gross profit is recognized in accordance with ASC 606, Revenue from Contracts with Customers and all the related amendments (&#8220;new revenue standard&#8221;) to all contracts. Sales revenue from the sale of our Nano Reactors is recognized when products are shipped from our manufacturing facilities as this is our sole performance obligation under these contracts and we have no continuing obligation to the customer. Accordingly, the Company estimates and recognizes the corresponding gross profit at the time of shipment of the Nano reactor hardware, subject to variable consideration constraints, in accordance to ASC 606.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">Specifically, the Company has determined that the gross profit to be earned from its distributor as a variable consideration that requires estimation in determining the transaction price, and as such all or a portion can be recognized using the most likely amount approach (subject to the variable consideration constraint). Estimates are available from our distributor which are considered in the determination of the most likely amount. However, given the lack of control over the sale to the end customer and the lack of history of prior sales, the Company considered these as a variable revenue constraint that required consideration and as such, the amount of revenue recognized is being limited to the actual amount of cash received under the contract which the Company has determined as not refundable and has concluded that future revenue reversal of such amount is not probable.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt"><b><i>&#160;</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt"><b><i>Share-Based Compensation</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt"><b><i>&#160;</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">The Company periodically issues stock options and warrants to employees and non-employees in non-capital raising transactions for services and for financing costs. The Company accounts for stock option and warrant grants issued and vesting to employees based on the authoritative guidance provided by the Financial Accounting Standards Board whereas the value of the award is measured on the date of grant and recognized over the vesting period. The Company accounts for stock option and warrant grants issued and vesting to non- employees in accordance with the authoritative guidance of the Financial Accounting Standards Board whereas the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, option grants are immediately vested, and the total stock-based compensation charge is recorded in the period of the measurement date.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">The fair value of the Company's common stock options and warrants grant is estimated using the Black-Scholes option pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the common stock options, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes option pricing model and based on actual experience. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future periods.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt"><b><i>Earnings( Loss) Per Share</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">The Company&#8217;s computation of earnings (loss) per share (EPS) includes basic and diluted EPS. Basic EPS is calculated by dividing the Company&#8217;s net income (loss) available to common stockholders by the weighted average number of common shares during the period. Shares of restricted stock subject to vesting are included in basic weighted average common shares outstanding from the time they vest. Diluted EPS reflects the potential dilution, using the treasury stock method that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the net income (loss) of the Company. In computing diluted EPS, the treasury stock method assumes that outstanding options and warrants are exercised, and the proceeds are used to purchase common stock at the average market price and there were no instruments that would result in issuance of additional shares during the period. <font style="font-family: Times New Roman, Times, Serif">&#160;</font></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">As of September 30, 2018, the Company had 11,000,000 stock options and 75,926,510 stock warrants outstanding to purchase shares of common stock that were not included in the diluted net loss per common share because their effect would be anti-dilutive.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt"><b><i>Recent Accounting Pronouncements</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt"><b><i>&#160;</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">In February 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-02, <i>Leases</i>. ASU 2016-02 requires a lessee to record a right of use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. ASU 2016-02 is effective for all interim and annual reporting periods beginning after December 15, 2018. Early adoption is permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. In July 2018, the FASB issued ASU 2018-11, <i>Targeted Improvements</i>, which allows for a cumulative-effect adjustment in the period the new lease standard is adopted and will not require restatement of prior periods. The Company is in the process of evaluating the impact of ASU 2016-02 and ASU 2018-11 on the Company&#8217;s financial statements and disclosures.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">In January 2016, the FASB issued ASU 2016-01, <i>Financial Instruments (Subtopic 825-10) - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities.</i> ASU 2016-01 provides guidance on how entities measure certain equity investments and present changes in the fair value. This standard requires that entities measure certain equity investments that do not result in consolidation and are not accounted for under the equity method at fair value and recognize any changes in fair value in net income. ASU 2016-01 is effective for fiscal years beginning after December 31, 2017. The Company adopted the guidance of ASU No. 2016-01 on July 1, 2018 and there was no effect to the Company&#8217;s consolidated financial statements.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company's present or future consolidated financial statements.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt"><u>Basis of Presentation</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles (&#34;GAAP&#34;) as promulgated in the United States of America (&#34;U.S.&#34;) and with instructions to Form 10-Q pursuant to the rules and regulations of Securities and Exchange Act of 1934, as amended (the &#34;Exchange Act&#34;) and Article 8-03 of Regulation S-X under the Exchange Act. Accordingly, these condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, we have included all adjustments considered necessary (consisting of normal recurring adjustments) for a fair presentation. Operating results for the three months ended September 30, 2018 are not indicative of the results that may be expected for the fiscal year ending June 30, 2019. You should read these unaudited condensed consolidated financial statements in conjunction with the audited financial statements and the notes thereto included in the Company's annual report on Form 10-K for the year ended June 30, 2018 filed on October 15, 2018. The condensed consolidated balance sheet as of June 30, 2018 has been derived from the audited financial statements included in the Form 10-K for that year.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt"></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt"><u>Going Concern</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. During the three months ended September 30, 2018, the Company incurred a net loss of $256,000 and used cash in operations of $284,000, and at September 30, 2018, had a working capital deficiency of $891,000 and a stockholders' deficit of $801,000.&#160;&#160;These factors, among others, raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year of the date that the financial statements are issued. In addition, the Company&#8217;s independent registered public accounting firm, in its report on the Company&#8217;s June 30, 2018 financial statements, has expressed substantial doubt about the Company&#8217;s ability to continue as a going concern. The accompanying condensed consolidated financial statements do not include adjustments that may result from an inability of the Company to continue as a going concern.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">As of September 30, 2018, we had cash and cash equivalents on hand of $661,000 and are not generating sufficient revenues to fund operations. In addition to the funds on hand, management believes we may require additional funds to continue to operate our business. Management's plan is to generate income from operations by continuing to license our technology globally through our strategic partners, Desmet Ballestra Group (Desmet), GEA Westfalia, AG (GEA), and recent agreements with Alchemy Beverages, Inc.(ABI). Desmet has provided us monthly advances of $50,000 through August 2018 that was applied against gross profit share from reactor sales pursuant to a January 2016 agreement. Our agreement with Desmet expired on October 1, 2018, however, Desmet and CTi are actively pursuing to finalize a new three year term. We believe that a new license agreement with Desmet should be finalized during fiscal 2019. GEA has agreed to provide us monthly advances of $25,000 less applicable taxes through January 2020, to be applied against gross profit share from future sales pursuant to January 2017 agreement. In June 2018, we entered into two licensing agreements with ABI and anticipate to start receiving certain royalties payments and revenue stream from ABI in fiscal 2019.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">We may also attempt to raise additional debt and/or equity financing to fund operations and provide additional working capital. However, there is no assurance that such financing will be consummated or obtained in sufficient amounts necessary to meet the Company's needs, that the Company will be able to achieve profitable operations or that the Company will be able to meet its future contractual obligations. Should management fail to obtain such financing, the Company may curtail its operations.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt"><b><i>Principles of Consolidation</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt"><b><i>&#160;</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">The condensed consolidated financial statements include the accounts of Cavitation Technologies, Inc. and its wholly owned subsidiary Hydrodynamic Technology, Inc. Inter-company transactions and balances have been eliminated in consolidation.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt"></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt"><b><i>Fair Value Measurement</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt"><b><i>&#160;</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">FASB Accounting Standards Codification (&#34;ASC&#34;) 820-10 requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">The three levels of the fair value hierarchy are as follows:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font: 8pt Symbol">&#183;</font></td><td style="text-align: justify"><font style="font-size: 8pt">Level 1 - Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability to access.</font></td></tr></table> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font: 8pt Symbol">&#183;</font></td><td style="text-align: justify"><font style="font-size: 8pt">Level 2 - Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.</font></td></tr></table> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font: 8pt Symbol">&#183;</font></td><td style="text-align: justify"><font style="font-size: 8pt">Level 3 - Valuations based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</font></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">On September 30, 2018 and June 30, 2018, the fair values of cash and cash equivalents, accounts receivable, inventory and accounts payable and accrued expenses approximate their carrying values due to their short-term nature.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt"></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt"><b><i>Use of Estimates</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt"><b><i>&#160;</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date and reported amounts of revenue and expenses during the reporting period. Significant estimates are used in reserve for inventory obsolescence, impairment analysis for fixed assets, accrual of potential liabilities, deferred tax assets and valuing our stock options, warrants, and common stock issued for services, among other items. Actual results could differ from these estimates.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt"><b><i></i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt"><b><i>Revenue Recognition</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">Revenues from sale of reactors and the corresponding share in gross profit is recognized in accordance with ASC 606, Revenue from Contracts with Customers and all the related amendments (&#8220;new revenue standard&#8221;) to all contracts. Sales revenue from the sale of our Nano Reactors is recognized when products are shipped from our manufacturing facilities as this is our sole performance obligation under these contracts and we have no continuing obligation to the customer. Accordingly, the Company estimates and recognizes the corresponding gross profit at the time of shipment of the Nano reactor hardware, subject to variable consideration constraints, in accordance to ASC 606.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">Specifically, the Company has determined that the gross profit to be earned from its distributor as a variable consideration that requires estimation in determining the transaction price, and as such all or a portion can be recognized using the most likely amount approach (subject to the variable consideration constraint). Estimates are available from our distributor which are considered in the determination of the most likely amount. However, given the lack of control over the sale to the end customer and the lack of history of prior sales, the Company considered these as a variable revenue constraint that required consideration and as such, the amount of revenue recognized is being limited to the actual amount of cash received under the contract which the Company has determined as not refundable and has concluded that future revenue reversal of such amount is not probable.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt"><b><i></i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt"><b><i>Share-Based Compensation</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt"><b><i>&#160;</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">The Company periodically issues stock options and warrants to employees and non-employees in non-capital raising transactions for services and for financing costs. The Company accounts for stock option and warrant grants issued and vesting to employees based on the authoritative guidance provided by the Financial Accounting Standards Board whereas the value of the award is measured on the date of grant and recognized over the vesting period. The Company accounts for stock option and warrant grants issued and vesting to non- employees in accordance with the authoritative guidance of the Financial Accounting Standards Board whereas the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, option grants are immediately vested, and the total stock-based compensation charge is recorded in the period of the measurement date.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">The fair value of the Company's common stock options and warrants grant is estimated using the Black-Scholes option pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the common stock options, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes option pricing model and based on actual experience. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future periods.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt"></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt"><b><i>Earnings( Loss) Per Share</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">The Company&#8217;s computation of earnings (loss) per share (EPS) includes basic and diluted EPS. Basic EPS is calculated by dividing the Company&#8217;s net income (loss) available to common stockholders by the weighted average number of common shares during the period. Shares of restricted stock subject to vesting are included in basic weighted average common shares outstanding from the time they vest. Diluted EPS reflects the potential dilution, using the treasury stock method that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the net income (loss) of the Company. In computing diluted EPS, the treasury stock method assumes that outstanding options and warrants are exercised, and the proceeds are used to purchase common stock at the average market price and there were no instruments that would result in issuance of additional shares during the period. <font style="font-family: Times New Roman, Times, Serif">&#160;</font></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">As of September 30, 2018, the Company had 11,000,000 stock options and 75,926,510 stock warrants outstanding to purchase shares of common stock that were not included in the diluted net loss per common share because their effect would be anti-dilutive.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt"><b><i>Recent Accounting Pronouncements</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt"><b><i>&#160;</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">In February 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-02, <i>Leases</i>. ASU 2016-02 requires a lessee to record a right of use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. ASU 2016-02 is effective for all interim and annual reporting periods beginning after December 15, 2018. Early adoption is permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. In July 2018, the FASB issued ASU 2018-11, <i>Targeted Improvements</i>, which allows for a cumulative-effect adjustment in the period the new lease standard is adopted and will not require restatement of prior periods. The Company is in the process of evaluating the impact of ASU 2016-02 and ASU 2018-11 on the Company&#8217;s financial statements and disclosures.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">In January 2016, the FASB issued ASU 2016-01, <i>Financial Instruments (Subtopic 825-10) - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities.</i> ASU 2016-01 provides guidance on how entities measure certain equity investments and present changes in the fair value. This standard requires that entities measure certain equity investments that do not result in consolidation and are not accounted for under the equity method at fair value and recognize any changes in fair value in net income. ASU 2016-01 is effective for fiscal years beginning after December 31, 2017. The Company adopted the guidance of ASU No. 2016-01 on July 1, 2018 and there was no effect to the Company&#8217;s consolidated financial statements.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company's present or future consolidated financial statements.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt"></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt"><b>Note 3 - Stockholders' Deficit</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt"><b><i>Stock Options</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt"><b><i>&#160;</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">The Company has not adopted a formal stock option plan. However, it has assumed outstanding stock options resulting from the acquisition of its wholly-owned subsidiary, Hydrodynamic Technology, Inc. In addition, the Company has made periodic non- plan grants. A summary of the stock option activity during the three months ended September 30, 2018 is as follows:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt">&#160;</font></p> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Weighted-</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Average</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Weighted-</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Remaining</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Average</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Contractual</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Exercise</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Life</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">Options</font></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">Price</font></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">(Years)</font></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%"><font style="font-size: 8pt">Outstanding at June 30, 2018</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 12%; text-align: right"><font style="font-size: 8pt">11,378,754</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 12%; text-align: right"><font style="font-size: 8pt">0.31</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 12%; text-align: right"><font style="font-size: 8pt">2.23</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 9pt"><font style="font-size: 8pt">- Granted</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">-</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">-</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">-</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 9pt"><font style="font-size: 8pt">- Forfeited</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">(378,754</font></td><td style="text-align: left"><font style="font-size: 8pt">)</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">-</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">-</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 9pt"><font style="font-size: 8pt">- Exercised</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">-</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">-</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">-</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 9pt"><font style="font-size: 8pt">- Expired</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">-</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt; text-align: right"><font style="font-size: 8pt">-</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt; text-align: right"><font style="font-size: 8pt">-</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><font style="font-size: 8pt">Outstanding at September 30, 2018</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">11,000,000</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">$</font></td><td style="text-align: right"><font style="font-size: 8pt">0.03</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">2.00</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font-size: 8pt">Exercisable and vested at September 30, 2018</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">11,000,000</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">$</font></td><td style="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 8pt">0.03</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 8pt">2.00</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">As of September 30, 2018, all outstanding options are fully vested. There was no intrinsic value of the outstanding options as of September 30, 2018 as the exercise price of these options were greater than the market price. The following table summarizes additional information concerning options outstanding and exercisable at September 30, 2018.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="10" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">Options&#160;Outstanding</font></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">Options&#160;Exercisable</font></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Weighted</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Weighted</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Weighted</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Average</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Average</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Average</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Exercise</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Number</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Remaining</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Exercise</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Number</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Remaining</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">Price</font></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">of&#160;Shares</font></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">Life&#160;(Years)</font></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">Price</font></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">of&#160;Shares</font></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">Life&#160;(Years)</font></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 14%; text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 14%; text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 14%; text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 14%; text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 14%; text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 13%; text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><font style="font-size: 8pt">$</font></td><td style="text-align: right"><font style="font-size: 8pt">0.03</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">11,000,000</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">2.00</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">$</font></td><td style="text-align: right"><font style="font-size: 8pt">0.03</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">11,000,000</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">2.00</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt"><b><i>&#160;</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt"><b><i>Warrants</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">A summary of the Company's warrant activity and related information for the three months ended on September 30, 2018 is as follows.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Weighted-</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Average</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Weighted-</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Remaining</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Average</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Contractual</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Exercise</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Life</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt"><b>Warrants</b></font></td><td style="white-space: nowrap; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; text-align: center; padding-bottom: 1pt"></td><td style="white-space: nowrap; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">Price</font></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">(Years)</font></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td colspan="2"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td colspan="2"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%"><font style="font-size: 8pt">Outstanding at June 30, 2018</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 15%; text-align: right"><font style="font-size: 8pt">75,926,510</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 15%; text-align: right"><font style="font-size: 8pt">0.06</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 15%; text-align: right"><font style="font-size: 8pt">3.81</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><font style="font-size: 8pt">Granted</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">-</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">-</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">-</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><font style="font-size: 8pt">Exercised</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">-</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"><font style="font-size: 8pt">Expired</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">-</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt; text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt; text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><font style="font-size: 8pt">Outstanding at September 30, 2018</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">75,926,510</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">0.06</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">3.56</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font-size: 8pt">Vested and exercisable at September 30, 2018</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">75,926,510</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">$</font></td><td style="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 8pt">0.06</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 8pt">3.56</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">As of September 30, 2018, all outstanding warrants are fully vested. There was no intrinsic value of the outstanding warrants as of September 30, 2018 as the exercise price of these warrants were greater than the market price. The following table summarizes additional information concerning warrants outstanding and exercisable at September 30, 2018.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="10" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">Warrants Outstanding</font></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">Warrants Exercisable</font></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Weighted</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Weighted</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Weighted</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Average</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Average</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Average</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Exercise</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Number</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Remaining</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Exercise</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Number</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Exercise</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">Price</font></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">of Shares</font></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">Life (Years)</font></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">Price</font></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">of Shares</font></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">Price</font></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 20%; text-align: center"><font style="font-size: 8pt">$0.03 - 0.07</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 13%; text-align: right"><font style="font-size: 8pt">55,599,851</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 13%; text-align: right"><font style="font-size: 8pt">6.50</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 13%; text-align: right"><font style="font-size: 8pt">0.05</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 13%; text-align: right"><font style="font-size: 8pt">55,599,851</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 13%; text-align: right"><font style="font-size: 8pt">0.05</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center; padding-bottom: 1pt"><font style="font-size: 8pt">$0.12</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">20,326,659</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt; text-align: right"><font style="font-size: 8pt">3.00</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">$</font></td><td style="padding-bottom: 1pt; text-align: right"><font style="font-size: 8pt">0.12</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">20,326,659</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">$</font></td><td style="padding-bottom: 1pt; text-align: right"><font style="font-size: 8pt">0.12</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">75,926,510</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">75,926,510</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt"><b>&#160;</b></font></p> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Weighted-</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Average</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Weighted-</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Remaining</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Average</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Contractual</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Exercise</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Life</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">Options</font></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">Price</font></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">(Years)</font></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%"><font style="font-size: 8pt">Outstanding at June 30, 2018</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 12%; text-align: right"><font style="font-size: 8pt">11,378,754</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 12%; text-align: right"><font style="font-size: 8pt">0.31</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 12%; text-align: right"><font style="font-size: 8pt">2.23</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 9pt"><font style="font-size: 8pt">- Granted</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">-</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">-</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">-</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 9pt"><font style="font-size: 8pt">- Forfeited</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">(378,754</font></td><td style="text-align: left"><font style="font-size: 8pt">)</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">-</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">-</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 9pt"><font style="font-size: 8pt">- Exercised</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">-</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">-</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">-</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 9pt"><font style="font-size: 8pt">- Expired</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">-</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt; text-align: right"><font style="font-size: 8pt">-</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt; text-align: right"><font style="font-size: 8pt">-</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><font style="font-size: 8pt">Outstanding at September 30, 2018</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">11,000,000</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">$</font></td><td style="text-align: right"><font style="font-size: 8pt">0.03</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">2.00</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font-size: 8pt">Exercisable and vested at September 30, 2018</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">11,000,000</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">$</font></td><td style="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 8pt">0.03</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 8pt">2.00</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="10" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">Options&#160;Outstanding</font></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">Options&#160;Exercisable</font></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Weighted</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Weighted</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Weighted</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Average</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Average</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Average</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Exercise</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Number</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Remaining</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Exercise</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Number</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Remaining</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">Price</font></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">of&#160;Shares</font></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">Life&#160;(Years)</font></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">Price</font></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">of&#160;Shares</font></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">Life&#160;(Years)</font></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 14%; text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 14%; text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 14%; text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 14%; text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 14%; text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 13%; text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><font style="font-size: 8pt">$</font></td><td style="text-align: right"><font style="font-size: 8pt">0.03</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">11,000,000</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">2.00</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">$</font></td><td style="text-align: right"><font style="font-size: 8pt">0.03</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">11,000,000</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">2.00</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Weighted-</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Average</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Weighted-</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Remaining</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Average</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Contractual</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Exercise</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Life</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt"><b>Warrants</b></font></td><td style="white-space: nowrap; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; text-align: center; padding-bottom: 1pt"></td><td style="white-space: nowrap; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">Price</font></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">(Years)</font></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td colspan="2"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td colspan="2"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%"><font style="font-size: 8pt">Outstanding at June 30, 2018</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 15%; text-align: right"><font style="font-size: 8pt">75,926,510</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 15%; text-align: right"><font style="font-size: 8pt">0.06</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 15%; text-align: right"><font style="font-size: 8pt">3.81</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><font style="font-size: 8pt">Granted</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">-</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">-</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">-</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><font style="font-size: 8pt">Exercised</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">-</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"><font style="font-size: 8pt">Expired</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">-</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt; text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt; text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><font style="font-size: 8pt">Outstanding at September 30, 2018</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">75,926,510</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">0.06</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="text-align: right"><font style="font-size: 8pt">3.56</font></td><td style="text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font-size: 8pt">Vested and exercisable at September 30, 2018</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">75,926,510</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">$</font></td><td style="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 8pt">0.06</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 8pt">3.56</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="10" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">Warrants Outstanding</font></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">Warrants Exercisable</font></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Weighted</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Weighted</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Weighted</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Average</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Average</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; text-align: center"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Average</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Exercise</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Number</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Remaining</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Exercise</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Number</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><font style="font-size: 8pt">Exercise</font></td><td style="white-space: nowrap; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">Price</font></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">of Shares</font></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">Life (Years)</font></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">Price</font></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">of Shares</font></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">Price</font></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td> <td colspan="2" style="text-align: right"><font style="font-size: 8pt">&#160;</font></td><td><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 20%; text-align: center"><font style="font-size: 8pt">$0.03 - 0.07</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 13%; text-align: right"><font style="font-size: 8pt">55,599,851</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 13%; text-align: right"><font style="font-size: 8pt">6.50</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 13%; text-align: right"><font style="font-size: 8pt">0.05</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 13%; text-align: right"><font style="font-size: 8pt">55,599,851</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="width: 1%"><font style="font-size: 8pt">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font-size: 8pt">$</font></td><td style="width: 13%; text-align: right"><font style="font-size: 8pt">0.05</font></td><td style="width: 1%; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center; padding-bottom: 1pt"><font style="font-size: 8pt">$0.12</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">20,326,659</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt; text-align: right"><font style="font-size: 8pt">3.00</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">$</font></td><td style="padding-bottom: 1pt; text-align: right"><font style="font-size: 8pt">0.12</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 8pt">20,326,659</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 1pt"><font style="font-size: 8pt">&#160;</font></td> <td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">$</font></td><td style="padding-bottom: 1pt; text-align: right"><font style="font-size: 8pt">0.12</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">75,926,510</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font-size: 8pt">75,926,510</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">&#160;</font></td> <td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 8pt">&#160;</font></td><td style="padding-bottom: 2.5pt; text-align: left"><font style="font-size: 8pt">&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt"><b></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt"><b>Note 4 - Commitments and Contingencies</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt"><u>Royalty Agreements</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">On July 1, 2008, our wholly owned subsidiary entered into Patent Assignment Agreements with two parties, our President and Technology Development Supervisor, where certain devices and methods involved in the hydrodynamic cavitation processes invented by the President and the Technology Development Supervisor have been assigned to the Subsidiary.&#160;&#160;In exchange, the Subsidiary agreed to pay a royalty of 5% of gross revenues to each of the President and Technology Development Supervisor for licensing of the technology and leasing of the related equipment embodying the technology. These agreements were subsequently assumed by Cavitation Technologies on May 13, 2010 from its subsidiary.&#160;The Company's President and Technology Development Supervisor both waived their rights to receive royalty payments that have accrued, or that may accrue, on any gross revenue generated through September 30, 2018.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">On April 30, 2008 and as amended on November 22, 2010, our wholly owned subsidiary entered into an employment agreement with our former Director of Chemical and Analytical Department (the &#34;Inventor&#34;) to receive an amount equal to 5% of actual gross royalties received from the royalty stream in the first year in which the Company receives royalty payments from the patent which the Inventor was the legally named inventor, and 3% of actual gross royalties received by the Company resulting from the patent in each subsequent year. As of September 30, 2018, no patents have been granted in which this person is the legally named inventor.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt"></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt"><b>Note 2 - Agreement with Distributors</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt"><i>&#160;</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt"><i><u>Desmet Ballestra Agreement</u></i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">On January 22, 2016, the Company signed a three-year agreement with Desmet for the sale and marketing of the Company&#8217;s Nano reactor system. As part of the agreement, Desmet provided, under certain conditions, limited monthly advance payments of $50,000 against future gross profit share to CTi through August 2018. The agreement expired on October 1, 2018 and Desmet and CTi are working on a new three year licensing agreement which we estimated will be finalized during fiscal 2019.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">The Company recognizes revenue from sale of reactors upon shipment and acceptance by Desmet, as the Company has no further obligations to Desmet other than the reactor&#8217;s two-year standard warranty. In addition, Desmet pays for such reactors on credit terms and the amount of the sale is recorded as a receivable upon acceptance by Desmet. The Company also receives a share in gross margin or profit from the sale of Desmet&#8217;s integrated neutralization system to its customer of which the reactors are an integral component, however, such amount is subject to adjustment based on certain factors including costs over run. The Company recognizes the gross profit at the time of shipment of the Nano reactor hardware in accordance to ASC 606 as such shipment is deemed to be the only performance obligation and the Company has no more continuing obligation to Desmet. In addition, the Company has no control with regards to the sale and installation of Nano Neutralization System, between our distributor and the end customer. The Company has determined that the gross profit to be earned from Desmet as a variable consideration that requires estimation in determining the transaction price, and as such all or a portion can be recognized using the most likely amount approach (subject to the variable consideration constraint). Estimates are available from Desmet which are considered in the determination of the most likely amount. However, given the lack of control over the sale to the end customer and the lack of history of prior sales, the Company considered these as a variable revenue constraint that required consideration. Thus, the amount of revenue recognized is being limited to the actual amount of cash received under the contract which the Company has determined as not refundable and preclude any probable of future revenue reversal. Further, Company has been able to develop an expectation of the actual collection based on its historical experience.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">During the three months ended September 30, 2018 and 2017, the Company recognized revenue of $55,000 and $340,000, respectively, related to the shipment and acceptance of reactors to Desmet.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt"><i>&#160;</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt"><i><u>GEA Westfalia Agreement</u></i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt; background-color: white">In January 2017 we entered into a global technology license, R&#38;D and marketing agreement with respect to our patented Nano Reactor&#8482; technology, processes and applications. Under the agreement, GEA has been granted a worldwide exclusive license to integrate our patented technology into water treatment application, milk and juice pasteurization, and certain food related processes. The license agreement between us and GEA has a three-year term and provides for the payment of $300,000 per year in advanced license fees or share in gross margin or profit to us. </font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt; background-color: white">Revenues from sale of reactors and share in gross profit is being recognized in accordance with current accounting guidelines as previously discussed in the Desmet Ballestra Agreement.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt; background-color: white">As of June 30, 2018, outstanding advances from GEA to be applied to share in gross profit in future period amounted to $427,000. During the period ended September 30, 2018, we received additional advances totaling $50,000 from GEA. As of September 30, 2018, outstanding advance from GEA amounted to $477,000. </font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">There were no reactor sales or gross profit or margin revenue recognized during the period ended September 30, 2018.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt"><i><u>Alchemy Beverages, Inc. Agreement</u></i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">In June 2018, the Company entered into licensing agreements with Alchemy Beverages Inc. (ABI). Pursuant to the licensing agreements, ABI has the exclusive global distribution rights for the Company&#8217;s patented and patent pending technology for the processing of alcoholic beverages. The Company has agreed to assist in the installation and maintenance of the nano reactor systems for ABI and will receive royalty payments ranging from 1% to 3% on all net revenues, as defined, of ABI for the life of the applicable patents. In addition, the Company will receive leasing, consulting, and manufacturing fees as defined. In addition, on a future transaction involving the sale of ABI, the Company will receive approximately 10% of the transaction price (with a minimum of $5 million) and in the event ABI becomes a public entity, the Company will receive approximately 10% of ABI&#8217;s shares. There was no revenue recognized during the period ended September 30, 2018 pursuant to these agreements.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">At September 30, 2018, the Company owns 19.9% of ABI. The investment in ABI has no value assigned to it, which approximates its fair value.</font></p> -891000 11000000 75926510 .199 0.03 P2Y 75926510 0 0 -284000 19000 EX-101.SCH 8 cvat-20180930.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Organization and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - 2. Agreement with Distributors link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - 3. Stockholders' Deficit link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - 4. Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - 1. Organization and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - 3. Stockholders' Deficit (Tables) link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - 1. Organization and Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - 2. Agreement with Distributors (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - 3. Stockholders' Deficit (Details - Option activity) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - 3. Stockholders' Deficit (Details - Options by exercise price) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - 3. Stockholders' Deficit (Details - Warrant activity) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - 3. Stockholders' Deficit (Details - Warrants by exercise price) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - 3. Stockholders' Deficit (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 cvat-20180930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 10 cvat-20180930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 11 cvat-20180930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Counterparty Name [Axis] GEA Westfalia [Member] Award Type [Axis] Options [Member] Exercise Price Range [Axis] $0.03 Exercise Price [Member] Warrants [Member] $0.03-$0.07 [Member] $0.12 [Member] Equity Components [Axis] Series A Preferred Stock Antidilutive Securities [Axis] Desmet Ballestra [Member] Alchemy Beverages [Member] Retained Earnings / Accumulated Deficit Common Stock Additional Paid-In Capital Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Emerging Growth Company Entity Small Business Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] Current assets Cash and cash equivalents Accounts receivable Inventory Total current assets Property and equipment, net Other assets Total assets LIABILITIES AND STOCKHOLDERS' DEFICIT Current liabilities: Accounts payable and accrued expenses Accrued payroll and payroll taxes due to officers Related party payable Advances from distributor, net Total current liabilities Commitments and contingencies Stockholders' deficit: Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of September 30, 2018 and June 30, 2018, respectively Common stock, $0.001 par value, 1,000,000,000 shares authorized, 196,797,906 shares issued and outstanding as of September 30, 2018 and June 30, 2018, respectively Additional paid-in capital Accumulated deficit Total stockholders' deficit Total liabilities and stockholders' deficit Preferred Stock, par value Preferred Stock, shares authorized Preferred Stock, shares issued Preferred Stock, shares outstanding Common Stock, par value Common Stock, shares authorized Common Stock, shares issued Common Stock, shares outstanding Income Statement [Abstract] Revenue Cost of revenue Gross profit General and administrative expenses Research and development expenses Total operating expenses Net loss Net loss per share, Basic and Diluted Weighted average shares outstanding, Basic and Diluted Statement [Table] Statement [Line Items] Beginning balance, shares Beginning balance, value Issuance of common stock for services, shares Issuance of common stock for services, value Cancellation of common stock granted to Director, shares Cancellation of common stock granted to Director, value Fair value of warrants issued for services Net loss Ending balance, shares Ending balance, value Statement of Cash Flows [Abstract] Operating activities: Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Depreciation and amortization Commoon stock issued to consultants Fair value of vested warrants Gain on settlement of accrued payroll Effect of changes in: Accounts receivable Inventory Other assets Accounts payable and accrued expenses Accrued payroll and payroll taxes due to officers Advances from distributor Net cash provided by (used in) operating activities Investing activities: Purchase of property and equipment Net cash used in investing activities Net change in cash Cash, beginning of period Cash, end of period Supplemental disclosures of cash flow information: Cash paid for interest Cash paid for income taxes Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization and Summary of Significant Accounting Policies Agreement With Distributors Agreement with Distributors Equity [Abstract] Stockholders' Deficit Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Accounting Policies [Abstract] Basis of Presentation Going Concern Principles of Consolidation Fair Value Measurement Use of Estimates Revenue Recognition Cash Accounts Receivable Inventory Property and Equipment Share-Based Compensation Income Taxes Advertising Costs Research and Development Costs Warranty Policy Earnings (Loss) Per Share Recent Accounting Pronouncements Dependence on Desmet Ballestra Reclassification Stock Option activity table Schedule of options outstanding and exercisable Schedule of warrant activity Schedule of warrants outstanding and exercisable Net income (loss) Stockholders deficit Cash used in operations Working capital Antidilutive shares outstanding Product and Service [Axis] Revenues Outstanding advances Proceeds from advances Ownership percentage Options Options outstanding, beginning balance Options granted Options forfeited Options exercised Options expired Options outstanding, ending balance Options exercisable Weighted Average Exercise Price Weighted average exercise price, options outstanding, beginning price Weighted average exercise price, options granted Weighted average exercise price, options forfeited Weighted average exercise price, options exercised Weighted average exercise price, options expired Weighted average exercise price, options outstanding, ending price Weighted average exercise price, options exercisable Weighted Average Remaining Contractual Life (Years) Weighted average remaining contractual life, options outstanding Weighted average remaining contractual life, options exercisable Number of shares outstanding Weighted average remaining life options outstanding Weighted average exercise price options outstanding Number of shares exercisable Weighted average remaining life options exercisable Warrants Warrants outstanding, beginning balance Warrants granted Warrants exercised Warrants expired Warrants outstanding, ending balance Warrants exercisable Weighted Average Exercise Price Weighted average exercise price, warrants outstanding, beginning price Weighted average exercise price, warrants granted Weighted average exercise price, warrants outstanding, ending price Weighted average exercise price, warrants exercisable Weighted Average Remaining Contractual Life Weighted average remaining contractual life Weighted average remaining contractual life, warrants exercisable Number of warrant shares outstanding Weighted average remaining life warrants outstanding Weighted average exercise price warrants outstanding Number of warrant shares exercisable Weighted average exercise price warrants exercisable Intrinsic value of options outstanding Intrinsic value of warrants outstanding Schedule of warrants outstanding and exercisable [Table Text Block] Warrants [Abstract] Weighted Average Exercise Price [Abstract] Weighted Average Remaining Contractual Life [Abstract] Weighted average exercise price warrants exercisable Working capital Warrants exercisable Weighted average remaining contractual life, warrants exercisable Assets, Current Assets Liabilities, Current Liabilities and Equity Gross Profit Operating Expenses Shares, Outstanding Stock Repurchased During Period, Shares Stock Repurchased During Period, Value Gain (Loss) on Extinguishment of Debt Increase (Decrease) in Accounts Receivable Increase (Decrease) in Inventories Increase (Decrease) in Other Operating Assets Increase (Decrease) in Accounts Payable and Accrued Liabilities Increase (Decrease) in Employee Related Liabilities Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Cash and Cash Equivalents, Period Increase (Decrease) Inventory, Policy [Policy Text Block] Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations EX-101.PRE 12 cvat-20180930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 13 R1.htm IDEA: XBRL DOCUMENT v3.10.0.1
Document and Entity Information - shares
3 Months Ended
Sep. 30, 2018
Nov. 12, 2018
Document And Entity Information    
Entity Registrant Name Cavitation Technologies, Inc.  
Entity Central Index Key 0001376793  
Document Type 10-Q  
Document Period End Date Sep. 30, 2018  
Amendment Flag false  
Current Fiscal Year End Date --06-30  
Is Entity's Reporting Status Current? Yes  
Entity Filer Category Non-accelerated Filer  
Entity Emerging Growth Company false  
Entity Small Business true  
Entity Common Stock, Shares Outstanding   196,997,906
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2019  
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
Sep. 30, 2018
Jun. 30, 2018
Current assets    
Cash and cash equivalents $ 661,000 $ 945,000
Accounts receivable 55,000 0
Inventory 29,000 34,000
Total current assets 745,000 979,000
Property and equipment, net 80,000 90,000
Other assets 10,000 10,000
Total assets 835,000 1,079,000
Current liabilities:    
Accounts payable and accrued expenses 295,000 307,000
Accrued payroll and payroll taxes due to officers 863,000 889,000
Related party payable 1,000 1,000
Advances from distributor, net 477,000 427,000
Total current liabilities 1,636,000 1,624,000
Commitments and contingencies
Stockholders' deficit:    
Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of September 30, 2018 and June 30, 2018, respectively 0 0
Common stock, $0.001 par value, 1,000,000,000 shares authorized, 196,797,906 shares issued and outstanding as of September 30, 2018 and June 30, 2018, respectively 196,998 196,998
Additional paid-in capital 22,641,002 22,641,002
Accumulated deficit (23,639,000) (23,383,000)
Total stockholders' deficit (801,000) (545,000)
Total liabilities and stockholders' deficit $ 835,000 $ 1,079,000
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares
Sep. 30, 2018
Jun. 30, 2018
Statement of Financial Position [Abstract]    
Preferred Stock, par value $ 0.001 $ 0.001
Preferred Stock, shares authorized 10,000,000 10,000,000
Preferred Stock, shares issued 0 0
Preferred Stock, shares outstanding 0 0
Common Stock, par value $ 0.001 $ 0.001
Common Stock, shares authorized 1,000,000,000 1,000,000,000
Common Stock, shares issued 196,997,906 196,997,906
Common Stock, shares outstanding 196,997,906 196,997,906
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Income Statement [Abstract]    
Revenue $ 55,000 $ 340,000
Cost of revenue 5,000 19,000
Gross profit 50,000 321,000
General and administrative expenses 304,000 460,000
Research and development expenses 2,000 3,000
Total operating expenses 306,000 463,000
Net loss $ (256,000) $ (142,000)
Net loss per share, Basic and Diluted $ (0.00) $ (0.00)
Weighted average shares outstanding, Basic and Diluted 196,797,906 197,193,558
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) - 3 months ended Sep. 30, 2018 - USD ($)
Series A Preferred Stock
Common Stock
Additional Paid-In Capital
Retained Earnings / Accumulated Deficit
Total
Beginning balance, shares at Jun. 30, 2018 0 196,797,906      
Beginning balance, value at Jun. 30, 2018 $ 0 $ 196,998 $ 22,641,002 $ (23,383,000) $ (545,000)
Net loss       (256,000) (256,000)
Ending balance, shares at Sep. 30, 2018 0 196,797,906      
Ending balance, value at Sep. 30, 2018 $ 0 $ 196,998 $ 22,641,002 $ (23,639,000) $ (801,000)
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
3 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Operating activities:    
Net loss $ (256,000) $ (142,000)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:    
Depreciation and amortization 10,000 11,000
Commoon stock issued to consultants 0 16,000
Effect of changes in:    
Accounts receivable (55,000) (155,000)
Inventory 5,000 19,000
Accounts payable and accrued expenses (38,000) 90,000
Advances from distributor 50,000 180,000
Net cash provided by (used in) operating activities (284,000) 19,000
Investing activities:    
Net change in cash (284,000) 19,000
Cash, beginning of period 945,000 549,000
Cash, end of period 661,000 568,000
Supplemental disclosures of cash flow information:    
Cash paid for interest 0 0
Cash paid for income taxes $ 0 $ 1,600
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.10.0.1
Organization and Summary of Significant Accounting Policies
3 Months Ended
Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization and Summary of Significant Accounting Policies

Note 1 - Organization and Summary of Significant Accounting Policies

 

Cavitation Technologies, Inc. (referred to herein, unless otherwise indicated, as "the Company," "CTi," "we," "us," and "our") is a Nevada corporation originally incorporated under the name Bio Energy, Inc. CTi has developed, patented, and commercialized proprietary technology that may be used in liquid processing applications. CTi's patented Nano Reactor® is the critical component of CTi Nano Neutralization® System which is commercially proven to reduce operating costs and increase yields in refining vegetable oils. CTi has two patented systems and has filed several national and international patents to employ its proprietary technology in applications including, vegetable oil refining, wastewater treatment, biodiesel, algae oil extraction, and alcoholic beverage enhancement.

 

Basis of Presentation

 

The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles ("GAAP") as promulgated in the United States of America ("U.S.") and with instructions to Form 10-Q pursuant to the rules and regulations of Securities and Exchange Act of 1934, as amended (the "Exchange Act") and Article 8-03 of Regulation S-X under the Exchange Act. Accordingly, these condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, we have included all adjustments considered necessary (consisting of normal recurring adjustments) for a fair presentation. Operating results for the three months ended September 30, 2018 are not indicative of the results that may be expected for the fiscal year ending June 30, 2019. You should read these unaudited condensed consolidated financial statements in conjunction with the audited financial statements and the notes thereto included in the Company's annual report on Form 10-K for the year ended June 30, 2018 filed on October 15, 2018. The condensed consolidated balance sheet as of June 30, 2018 has been derived from the audited financial statements included in the Form 10-K for that year.

 

Going Concern

 

The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. During the three months ended September 30, 2018, the Company incurred a net loss of $256,000 and used cash in operations of $284,000, and at September 30, 2018, had a working capital deficiency of $891,000 and a stockholders' deficit of $801,000.  These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued. In addition, the Company’s independent registered public accounting firm, in its report on the Company’s June 30, 2018 financial statements, has expressed substantial doubt about the Company’s ability to continue as a going concern. The accompanying condensed consolidated financial statements do not include adjustments that may result from an inability of the Company to continue as a going concern.

 

As of September 30, 2018, we had cash and cash equivalents on hand of $661,000 and are not generating sufficient revenues to fund operations. In addition to the funds on hand, management believes we may require additional funds to continue to operate our business. Management's plan is to generate income from operations by continuing to license our technology globally through our strategic partners, Desmet Ballestra Group (Desmet), GEA Westfalia, AG (GEA), and recent agreements with Alchemy Beverages, Inc.(ABI). Desmet has provided us monthly advances of $50,000 through August 2018 that was applied against gross profit share from reactor sales pursuant to a January 2016 agreement. Our agreement with Desmet expired on October 1, 2018, however, Desmet and CTi are actively pursuing to finalize a new three year term. We believe that a new license agreement with Desmet should be finalized during fiscal 2019. GEA has agreed to provide us monthly advances of $25,000 less applicable taxes through January 2020, to be applied against gross profit share from future sales pursuant to January 2017 agreement. In June 2018, we entered into two licensing agreements with ABI and anticipate to start receiving certain royalties payments and revenue stream from ABI in fiscal 2019.

 

We may also attempt to raise additional debt and/or equity financing to fund operations and provide additional working capital. However, there is no assurance that such financing will be consummated or obtained in sufficient amounts necessary to meet the Company's needs, that the Company will be able to achieve profitable operations or that the Company will be able to meet its future contractual obligations. Should management fail to obtain such financing, the Company may curtail its operations.

 

Principles of Consolidation

 

The condensed consolidated financial statements include the accounts of Cavitation Technologies, Inc. and its wholly owned subsidiary Hydrodynamic Technology, Inc. Inter-company transactions and balances have been eliminated in consolidation.

 

Fair Value Measurement

 

FASB Accounting Standards Codification ("ASC") 820-10 requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties.

 

The three levels of the fair value hierarchy are as follows:

 

·Level 1 - Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability to access.
·Level 2 - Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.
·Level 3 - Valuations based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

 

On September 30, 2018 and June 30, 2018, the fair values of cash and cash equivalents, accounts receivable, inventory and accounts payable and accrued expenses approximate their carrying values due to their short-term nature.

 

Use of Estimates

 

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date and reported amounts of revenue and expenses during the reporting period. Significant estimates are used in reserve for inventory obsolescence, impairment analysis for fixed assets, accrual of potential liabilities, deferred tax assets and valuing our stock options, warrants, and common stock issued for services, among other items. Actual results could differ from these estimates.

 

Revenue Recognition

 

Revenues from sale of reactors and the corresponding share in gross profit is recognized in accordance with ASC 606, Revenue from Contracts with Customers and all the related amendments (“new revenue standard”) to all contracts. Sales revenue from the sale of our Nano Reactors is recognized when products are shipped from our manufacturing facilities as this is our sole performance obligation under these contracts and we have no continuing obligation to the customer. Accordingly, the Company estimates and recognizes the corresponding gross profit at the time of shipment of the Nano reactor hardware, subject to variable consideration constraints, in accordance to ASC 606.

 

Specifically, the Company has determined that the gross profit to be earned from its distributor as a variable consideration that requires estimation in determining the transaction price, and as such all or a portion can be recognized using the most likely amount approach (subject to the variable consideration constraint). Estimates are available from our distributor which are considered in the determination of the most likely amount. However, given the lack of control over the sale to the end customer and the lack of history of prior sales, the Company considered these as a variable revenue constraint that required consideration and as such, the amount of revenue recognized is being limited to the actual amount of cash received under the contract which the Company has determined as not refundable and has concluded that future revenue reversal of such amount is not probable.

 

Share-Based Compensation

 

The Company periodically issues stock options and warrants to employees and non-employees in non-capital raising transactions for services and for financing costs. The Company accounts for stock option and warrant grants issued and vesting to employees based on the authoritative guidance provided by the Financial Accounting Standards Board whereas the value of the award is measured on the date of grant and recognized over the vesting period. The Company accounts for stock option and warrant grants issued and vesting to non- employees in accordance with the authoritative guidance of the Financial Accounting Standards Board whereas the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, option grants are immediately vested, and the total stock-based compensation charge is recorded in the period of the measurement date.

 

The fair value of the Company's common stock options and warrants grant is estimated using the Black-Scholes option pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the common stock options, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes option pricing model and based on actual experience. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future periods.

 

Earnings( Loss) Per Share

 

The Company’s computation of earnings (loss) per share (EPS) includes basic and diluted EPS. Basic EPS is calculated by dividing the Company’s net income (loss) available to common stockholders by the weighted average number of common shares during the period. Shares of restricted stock subject to vesting are included in basic weighted average common shares outstanding from the time they vest. Diluted EPS reflects the potential dilution, using the treasury stock method that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the net income (loss) of the Company. In computing diluted EPS, the treasury stock method assumes that outstanding options and warrants are exercised, and the proceeds are used to purchase common stock at the average market price and there were no instruments that would result in issuance of additional shares during the period.  

 

As of September 30, 2018, the Company had 11,000,000 stock options and 75,926,510 stock warrants outstanding to purchase shares of common stock that were not included in the diluted net loss per common share because their effect would be anti-dilutive.

 

Recent Accounting Pronouncements

 

In February 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-02, Leases. ASU 2016-02 requires a lessee to record a right of use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. ASU 2016-02 is effective for all interim and annual reporting periods beginning after December 15, 2018. Early adoption is permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. In July 2018, the FASB issued ASU 2018-11, Targeted Improvements, which allows for a cumulative-effect adjustment in the period the new lease standard is adopted and will not require restatement of prior periods. The Company is in the process of evaluating the impact of ASU 2016-02 and ASU 2018-11 on the Company’s financial statements and disclosures.

 

In January 2016, the FASB issued ASU 2016-01, Financial Instruments (Subtopic 825-10) - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities. ASU 2016-01 provides guidance on how entities measure certain equity investments and present changes in the fair value. This standard requires that entities measure certain equity investments that do not result in consolidation and are not accounted for under the equity method at fair value and recognize any changes in fair value in net income. ASU 2016-01 is effective for fiscal years beginning after December 31, 2017. The Company adopted the guidance of ASU No. 2016-01 on July 1, 2018 and there was no effect to the Company’s consolidated financial statements.

 

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company's present or future consolidated financial statements.

XML 20 R8.htm IDEA: XBRL DOCUMENT v3.10.0.1
2. Agreement with Distributors
3 Months Ended
Sep. 30, 2018
Agreement With Distributors  
Agreement with Distributors

Note 2 - Agreement with Distributors

 

Desmet Ballestra Agreement

 

On January 22, 2016, the Company signed a three-year agreement with Desmet for the sale and marketing of the Company’s Nano reactor system. As part of the agreement, Desmet provided, under certain conditions, limited monthly advance payments of $50,000 against future gross profit share to CTi through August 2018. The agreement expired on October 1, 2018 and Desmet and CTi are working on a new three year licensing agreement which we estimated will be finalized during fiscal 2019.

 

The Company recognizes revenue from sale of reactors upon shipment and acceptance by Desmet, as the Company has no further obligations to Desmet other than the reactor’s two-year standard warranty. In addition, Desmet pays for such reactors on credit terms and the amount of the sale is recorded as a receivable upon acceptance by Desmet. The Company also receives a share in gross margin or profit from the sale of Desmet’s integrated neutralization system to its customer of which the reactors are an integral component, however, such amount is subject to adjustment based on certain factors including costs over run. The Company recognizes the gross profit at the time of shipment of the Nano reactor hardware in accordance to ASC 606 as such shipment is deemed to be the only performance obligation and the Company has no more continuing obligation to Desmet. In addition, the Company has no control with regards to the sale and installation of Nano Neutralization System, between our distributor and the end customer. The Company has determined that the gross profit to be earned from Desmet as a variable consideration that requires estimation in determining the transaction price, and as such all or a portion can be recognized using the most likely amount approach (subject to the variable consideration constraint). Estimates are available from Desmet which are considered in the determination of the most likely amount. However, given the lack of control over the sale to the end customer and the lack of history of prior sales, the Company considered these as a variable revenue constraint that required consideration. Thus, the amount of revenue recognized is being limited to the actual amount of cash received under the contract which the Company has determined as not refundable and preclude any probable of future revenue reversal. Further, Company has been able to develop an expectation of the actual collection based on its historical experience.

 

During the three months ended September 30, 2018 and 2017, the Company recognized revenue of $55,000 and $340,000, respectively, related to the shipment and acceptance of reactors to Desmet.

 

GEA Westfalia Agreement

 

In January 2017 we entered into a global technology license, R&D and marketing agreement with respect to our patented Nano Reactor™ technology, processes and applications. Under the agreement, GEA has been granted a worldwide exclusive license to integrate our patented technology into water treatment application, milk and juice pasteurization, and certain food related processes. The license agreement between us and GEA has a three-year term and provides for the payment of $300,000 per year in advanced license fees or share in gross margin or profit to us.

 

Revenues from sale of reactors and share in gross profit is being recognized in accordance with current accounting guidelines as previously discussed in the Desmet Ballestra Agreement.

 

As of June 30, 2018, outstanding advances from GEA to be applied to share in gross profit in future period amounted to $427,000. During the period ended September 30, 2018, we received additional advances totaling $50,000 from GEA. As of September 30, 2018, outstanding advance from GEA amounted to $477,000.

 

There were no reactor sales or gross profit or margin revenue recognized during the period ended September 30, 2018.

 

Alchemy Beverages, Inc. Agreement

 

In June 2018, the Company entered into licensing agreements with Alchemy Beverages Inc. (ABI). Pursuant to the licensing agreements, ABI has the exclusive global distribution rights for the Company’s patented and patent pending technology for the processing of alcoholic beverages. The Company has agreed to assist in the installation and maintenance of the nano reactor systems for ABI and will receive royalty payments ranging from 1% to 3% on all net revenues, as defined, of ABI for the life of the applicable patents. In addition, the Company will receive leasing, consulting, and manufacturing fees as defined. In addition, on a future transaction involving the sale of ABI, the Company will receive approximately 10% of the transaction price (with a minimum of $5 million) and in the event ABI becomes a public entity, the Company will receive approximately 10% of ABI’s shares. There was no revenue recognized during the period ended September 30, 2018 pursuant to these agreements.

 

At September 30, 2018, the Company owns 19.9% of ABI. The investment in ABI has no value assigned to it, which approximates its fair value.

XML 21 R9.htm IDEA: XBRL DOCUMENT v3.10.0.1
3. Stockholders' Deficit
3 Months Ended
Sep. 30, 2018
Equity [Abstract]  
Stockholders' Deficit

Note 3 - Stockholders' Deficit

 

Stock Options

 

The Company has not adopted a formal stock option plan. However, it has assumed outstanding stock options resulting from the acquisition of its wholly-owned subsidiary, Hydrodynamic Technology, Inc. In addition, the Company has made periodic non- plan grants. A summary of the stock option activity during the three months ended September 30, 2018 is as follows:

 

           Weighted- 
           Average 
       Weighted-   Remaining 
       Average   Contractual 
       Exercise   Life 
   Options   Price   (Years) 
             
Outstanding at June 30, 2018   11,378,754   $0.31    2.23 
- Granted   -    -    - 
- Forfeited   (378,754)   -    - 
- Exercised   -    -    - 
- Expired   -    -    - 
Outstanding at September 30, 2018   11,000,000   $0.03    2.00 
Exercisable and vested at September 30, 2018   11,000,000   $0.03    2.00 

 

As of September 30, 2018, all outstanding options are fully vested. There was no intrinsic value of the outstanding options as of September 30, 2018 as the exercise price of these options were greater than the market price. The following table summarizes additional information concerning options outstanding and exercisable at September 30, 2018.

 

    Options Outstanding   Options Exercisable 
        Weighted   Weighted       Weighted 
        Average   Average       Average 
Exercise   Number   Remaining   Exercise   Number   Remaining 
Price   of Shares   Life (Years)   Price   of Shares   Life (Years) 
                            
$0.03    11,000,000    2.00   $0.03    11,000,000    2.00 

 

Warrants

 

A summary of the Company's warrant activity and related information for the three months ended on September 30, 2018 is as follows.

 

           Weighted- 
           Average 
       Weighted-   Remaining 
       Average   Contractual 
       Exercise   Life 
Warrants     Price   (Years) 
             
Outstanding at June 30, 2018   75,926,510   $0.06    3.81 
Granted   -    -    - 
Exercised   -           
Expired   -           
Outstanding at September 30, 2018   75,926,510    0.06    3.56 
Vested and exercisable at September 30, 2018   75,926,510   $0.06    3.56 

 

As of September 30, 2018, all outstanding warrants are fully vested. There was no intrinsic value of the outstanding warrants as of September 30, 2018 as the exercise price of these warrants were greater than the market price. The following table summarizes additional information concerning warrants outstanding and exercisable at September 30, 2018.

 

   Warrants Outstanding   Warrants Exercisable 
       Weighted   Weighted       Weighted 
       Average   Average       Average 
Exercise  Number   Remaining   Exercise   Number   Exercise 
Price  of Shares   Life (Years)   Price   of Shares   Price 
                     
$0.03 - 0.07   55,599,851    6.50   $0.05    55,599,851   $0.05 
$0.12   20,326,659    3.00   $0.12    20,326,659   $0.12 
    75,926,510              75,926,510      

 

XML 22 R10.htm IDEA: XBRL DOCUMENT v3.10.0.1
4. Commitments and Contingencies
3 Months Ended
Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

Note 4 - Commitments and Contingencies

 

Royalty Agreements

 

On July 1, 2008, our wholly owned subsidiary entered into Patent Assignment Agreements with two parties, our President and Technology Development Supervisor, where certain devices and methods involved in the hydrodynamic cavitation processes invented by the President and the Technology Development Supervisor have been assigned to the Subsidiary.  In exchange, the Subsidiary agreed to pay a royalty of 5% of gross revenues to each of the President and Technology Development Supervisor for licensing of the technology and leasing of the related equipment embodying the technology. These agreements were subsequently assumed by Cavitation Technologies on May 13, 2010 from its subsidiary. The Company's President and Technology Development Supervisor both waived their rights to receive royalty payments that have accrued, or that may accrue, on any gross revenue generated through September 30, 2018.

 

On April 30, 2008 and as amended on November 22, 2010, our wholly owned subsidiary entered into an employment agreement with our former Director of Chemical and Analytical Department (the "Inventor") to receive an amount equal to 5% of actual gross royalties received from the royalty stream in the first year in which the Company receives royalty payments from the patent which the Inventor was the legally named inventor, and 3% of actual gross royalties received by the Company resulting from the patent in each subsequent year. As of September 30, 2018, no patents have been granted in which this person is the legally named inventor.

XML 23 R11.htm IDEA: XBRL DOCUMENT v3.10.0.1
1. Organization and Summary of Significant Accounting Policies (Policies)
3 Months Ended
Sep. 30, 2018
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

 

The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles ("GAAP") as promulgated in the United States of America ("U.S.") and with instructions to Form 10-Q pursuant to the rules and regulations of Securities and Exchange Act of 1934, as amended (the "Exchange Act") and Article 8-03 of Regulation S-X under the Exchange Act. Accordingly, these condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, we have included all adjustments considered necessary (consisting of normal recurring adjustments) for a fair presentation. Operating results for the three months ended September 30, 2018 are not indicative of the results that may be expected for the fiscal year ending June 30, 2019. You should read these unaudited condensed consolidated financial statements in conjunction with the audited financial statements and the notes thereto included in the Company's annual report on Form 10-K for the year ended June 30, 2018 filed on October 15, 2018. The condensed consolidated balance sheet as of June 30, 2018 has been derived from the audited financial statements included in the Form 10-K for that year.

Going Concern

Going Concern

 

The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. During the three months ended September 30, 2018, the Company incurred a net loss of $256,000 and used cash in operations of $284,000, and at September 30, 2018, had a working capital deficiency of $891,000 and a stockholders' deficit of $801,000.  These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued. In addition, the Company’s independent registered public accounting firm, in its report on the Company’s June 30, 2018 financial statements, has expressed substantial doubt about the Company’s ability to continue as a going concern. The accompanying condensed consolidated financial statements do not include adjustments that may result from an inability of the Company to continue as a going concern.

 

As of September 30, 2018, we had cash and cash equivalents on hand of $661,000 and are not generating sufficient revenues to fund operations. In addition to the funds on hand, management believes we may require additional funds to continue to operate our business. Management's plan is to generate income from operations by continuing to license our technology globally through our strategic partners, Desmet Ballestra Group (Desmet), GEA Westfalia, AG (GEA), and recent agreements with Alchemy Beverages, Inc.(ABI). Desmet has provided us monthly advances of $50,000 through August 2018 that was applied against gross profit share from reactor sales pursuant to a January 2016 agreement. Our agreement with Desmet expired on October 1, 2018, however, Desmet and CTi are actively pursuing to finalize a new three year term. We believe that a new license agreement with Desmet should be finalized during fiscal 2019. GEA has agreed to provide us monthly advances of $25,000 less applicable taxes through January 2020, to be applied against gross profit share from future sales pursuant to January 2017 agreement. In June 2018, we entered into two licensing agreements with ABI and anticipate to start receiving certain royalties payments and revenue stream from ABI in fiscal 2019.

 

We may also attempt to raise additional debt and/or equity financing to fund operations and provide additional working capital. However, there is no assurance that such financing will be consummated or obtained in sufficient amounts necessary to meet the Company's needs, that the Company will be able to achieve profitable operations or that the Company will be able to meet its future contractual obligations. Should management fail to obtain such financing, the Company may curtail its operations.

Principles of Consolidation

Principles of Consolidation

 

The condensed consolidated financial statements include the accounts of Cavitation Technologies, Inc. and its wholly owned subsidiary Hydrodynamic Technology, Inc. Inter-company transactions and balances have been eliminated in consolidation.

Fair Value Measurement

Fair Value Measurement

 

FASB Accounting Standards Codification ("ASC") 820-10 requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties.

 

The three levels of the fair value hierarchy are as follows:

 

·Level 1 - Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability to access.
·Level 2 - Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.
·Level 3 - Valuations based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

 

On September 30, 2018 and June 30, 2018, the fair values of cash and cash equivalents, accounts receivable, inventory and accounts payable and accrued expenses approximate their carrying values due to their short-term nature.

Use of Estimates

Use of Estimates

 

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date and reported amounts of revenue and expenses during the reporting period. Significant estimates are used in reserve for inventory obsolescence, impairment analysis for fixed assets, accrual of potential liabilities, deferred tax assets and valuing our stock options, warrants, and common stock issued for services, among other items. Actual results could differ from these estimates.

Revenue Recognition

Revenue Recognition

 

Revenues from sale of reactors and the corresponding share in gross profit is recognized in accordance with ASC 606, Revenue from Contracts with Customers and all the related amendments (“new revenue standard”) to all contracts. Sales revenue from the sale of our Nano Reactors is recognized when products are shipped from our manufacturing facilities as this is our sole performance obligation under these contracts and we have no continuing obligation to the customer. Accordingly, the Company estimates and recognizes the corresponding gross profit at the time of shipment of the Nano reactor hardware, subject to variable consideration constraints, in accordance to ASC 606.

 

Specifically, the Company has determined that the gross profit to be earned from its distributor as a variable consideration that requires estimation in determining the transaction price, and as such all or a portion can be recognized using the most likely amount approach (subject to the variable consideration constraint). Estimates are available from our distributor which are considered in the determination of the most likely amount. However, given the lack of control over the sale to the end customer and the lack of history of prior sales, the Company considered these as a variable revenue constraint that required consideration and as such, the amount of revenue recognized is being limited to the actual amount of cash received under the contract which the Company has determined as not refundable and has concluded that future revenue reversal of such amount is not probable.

Share-Based Compensation

Share-Based Compensation

 

The Company periodically issues stock options and warrants to employees and non-employees in non-capital raising transactions for services and for financing costs. The Company accounts for stock option and warrant grants issued and vesting to employees based on the authoritative guidance provided by the Financial Accounting Standards Board whereas the value of the award is measured on the date of grant and recognized over the vesting period. The Company accounts for stock option and warrant grants issued and vesting to non- employees in accordance with the authoritative guidance of the Financial Accounting Standards Board whereas the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, option grants are immediately vested, and the total stock-based compensation charge is recorded in the period of the measurement date.

 

The fair value of the Company's common stock options and warrants grant is estimated using the Black-Scholes option pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the common stock options, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes option pricing model and based on actual experience. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future periods.

Earnings (Loss) Per Share

Earnings( Loss) Per Share

 

The Company’s computation of earnings (loss) per share (EPS) includes basic and diluted EPS. Basic EPS is calculated by dividing the Company’s net income (loss) available to common stockholders by the weighted average number of common shares during the period. Shares of restricted stock subject to vesting are included in basic weighted average common shares outstanding from the time they vest. Diluted EPS reflects the potential dilution, using the treasury stock method that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the net income (loss) of the Company. In computing diluted EPS, the treasury stock method assumes that outstanding options and warrants are exercised, and the proceeds are used to purchase common stock at the average market price and there were no instruments that would result in issuance of additional shares during the period.  

 

As of September 30, 2018, the Company had 11,000,000 stock options and 75,926,510 stock warrants outstanding to purchase shares of common stock that were not included in the diluted net loss per common share because their effect would be anti-dilutive.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

In February 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-02, Leases. ASU 2016-02 requires a lessee to record a right of use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. ASU 2016-02 is effective for all interim and annual reporting periods beginning after December 15, 2018. Early adoption is permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. In July 2018, the FASB issued ASU 2018-11, Targeted Improvements, which allows for a cumulative-effect adjustment in the period the new lease standard is adopted and will not require restatement of prior periods. The Company is in the process of evaluating the impact of ASU 2016-02 and ASU 2018-11 on the Company’s financial statements and disclosures.

 

In January 2016, the FASB issued ASU 2016-01, Financial Instruments (Subtopic 825-10) - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities. ASU 2016-01 provides guidance on how entities measure certain equity investments and present changes in the fair value. This standard requires that entities measure certain equity investments that do not result in consolidation and are not accounted for under the equity method at fair value and recognize any changes in fair value in net income. ASU 2016-01 is effective for fiscal years beginning after December 31, 2017. The Company adopted the guidance of ASU No. 2016-01 on July 1, 2018 and there was no effect to the Company’s consolidated financial statements.

 

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company's present or future consolidated financial statements.

XML 24 R12.htm IDEA: XBRL DOCUMENT v3.10.0.1
3. Stockholders' Deficit (Tables)
3 Months Ended
Sep. 30, 2018
Equity [Abstract]  
Stock Option activity table
           Weighted- 
           Average 
       Weighted-   Remaining 
       Average   Contractual 
       Exercise   Life 
   Options   Price   (Years) 
             
Outstanding at June 30, 2018   11,378,754   $0.31    2.23 
- Granted   -    -    - 
- Forfeited   (378,754)   -    - 
- Exercised   -    -    - 
- Expired   -    -    - 
Outstanding at September 30, 2018   11,000,000   $0.03    2.00 
Exercisable and vested at September 30, 2018   11,000,000   $0.03    2.00 
Schedule of options outstanding and exercisable
    Options Outstanding   Options Exercisable 
        Weighted   Weighted       Weighted 
        Average   Average       Average 
Exercise   Number   Remaining   Exercise   Number   Remaining 
Price   of Shares   Life (Years)   Price   of Shares   Life (Years) 
                            
$0.03    11,000,000    2.00   $0.03    11,000,000    2.00 
Schedule of warrant activity
           Weighted- 
           Average 
       Weighted-   Remaining 
       Average   Contractual 
       Exercise   Life 
Warrants     Price   (Years) 
             
Outstanding at June 30, 2018   75,926,510   $0.06    3.81 
Granted   -    -    - 
Exercised   -           
Expired   -           
Outstanding at September 30, 2018   75,926,510    0.06    3.56 
Vested and exercisable at September 30, 2018   75,926,510   $0.06    3.56 
Schedule of warrants outstanding and exercisable
   Warrants Outstanding   Warrants Exercisable 
       Weighted   Weighted       Weighted 
       Average   Average       Average 
Exercise  Number   Remaining   Exercise   Number   Exercise 
Price  of Shares   Life (Years)   Price   of Shares   Price 
                     
$0.03 - 0.07   55,599,851    6.50   $0.05    55,599,851   $0.05 
$0.12   20,326,659    3.00   $0.12    20,326,659   $0.12 
    75,926,510              75,926,510      
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.10.0.1
1. Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($)
3 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Net income (loss) $ (256,000) $ (142,000)    
Stockholders deficit (801,000)   $ (545,000)  
Cash used in operations (284,000) 19,000    
Working capital (891,000)      
Cash and cash equivalents $ 661,000 $ 568,000 $ 945,000 $ 549,000
Options [Member]        
Antidilutive shares outstanding 11,000,000      
Warrants [Member]        
Antidilutive shares outstanding 75,926,510      
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.10.0.1
2. Agreement with Distributors (Details Narrative) - USD ($)
3 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Jun. 30, 2018
Revenues $ 55,000 $ 340,000  
Outstanding advances 477,000   $ 427,000
Proceeds from advances 50,000 180,000  
Desmet Ballestra [Member]      
Revenues 55,000 $ 340,000  
GEA Westfalia [Member]      
Outstanding advances 477,000   $ 427,000
Proceeds from advances 50,000    
Alchemy Beverages [Member]      
Revenues $ 0    
Ownership percentage 19.90%    
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.10.0.1
3. Stockholders' Deficit (Details - Option activity) - Options [Member] - $ / shares
3 Months Ended 12 Months Ended
Sep. 30, 2018
Jun. 30, 2018
Options    
Options outstanding, beginning balance 11,378,754 11,685,852
Options granted 0 0
Options forfeited (378,754) 0
Options exercised 0 0
Options expired 0 (307,098)
Options outstanding, ending balance 11,000,000 11,378,754
Options exercisable 11,000,000 11,378,754
Weighted Average Exercise Price    
Weighted average exercise price, options outstanding, beginning price $ 0.31 $ 0.37
Weighted average exercise price, options granted
Weighted average exercise price, options forfeited
Weighted average exercise price, options exercised
Weighted average exercise price, options expired
Weighted average exercise price, options outstanding, ending price 0.03 $ 0.31
Weighted average exercise price, options exercisable $ 0.03  
Weighted Average Remaining Contractual Life (Years)    
Weighted average remaining contractual life, options outstanding 2 years 2 years 2 months 23 days
Weighted average remaining contractual life, options exercisable 2 years  
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.10.0.1
3. Stockholders' Deficit (Details - Options by exercise price) - $0.03 Exercise Price [Member] - $ / shares
3 Months Ended
Sep. 30, 2018
Jun. 30, 2018
Number of shares outstanding   11,000,000
Weighted average remaining life options outstanding 2 years  
Weighted average exercise price options outstanding $ 0.03  
Number of shares exercisable   11,000,000
Weighted average remaining life options exercisable 2 years  
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.10.0.1
3. Stockholders' Deficit (Details - Warrant activity) - Warrants [Member] - $ / shares
3 Months Ended 12 Months Ended
Sep. 30, 2018
Jun. 30, 2018
Warrants    
Warrants outstanding, beginning balance 75,926,510 75,926,510
Warrants granted 0
Warrants exercised 0
Warrants expired 0
Warrants outstanding, ending balance 75,926,510 75,926,510
Warrants exercisable 75,926,510  
Weighted Average Exercise Price    
Weighted average exercise price, warrants outstanding, beginning price $ 0.06 $ 0.06
Weighted average exercise price, warrants outstanding, ending price 0.06 $ 0.06
Weighted average exercise price, warrants exercisable $ 0.06  
Weighted Average Remaining Contractual Life    
Weighted average remaining contractual life 3 years 6 months 22 days 3 years 9 months 22 days
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.10.0.1
3. Stockholders' Deficit (Details - Warrants by exercise price) - $ / shares
3 Months Ended 12 Months Ended
Sep. 30, 2018
Jun. 30, 2018
Jun. 30, 2017
$0.03-$0.07 [Member]      
Number of warrant shares outstanding 55,599,851    
Weighted average remaining life warrants outstanding 6 years 6 months    
Weighted average exercise price warrants outstanding $ 0.05    
Number of warrant shares exercisable 55,599,851    
Weighted average exercise price warrants exercisable $ 0.05    
$0.12 [Member]      
Number of warrant shares outstanding 20,326,659    
Weighted average remaining life warrants outstanding 3 years    
Weighted average exercise price warrants outstanding $ 0.12    
Number of warrant shares exercisable 20,326,659    
Weighted average exercise price warrants exercisable $ 0.12    
Warrants [Member]      
Number of warrant shares outstanding 75,926,510 75,926,510 75,926,510
Weighted average remaining life warrants outstanding 3 years 6 months 22 days 3 years 9 months 22 days  
Weighted average exercise price warrants outstanding $ 0.06 $ 0.06 $ 0.06
Number of warrant shares exercisable 75,926,510    
Weighted average exercise price warrants exercisable $ 0.06    
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.10.0.1
3. Stockholders' Deficit (Details Narrative)
Sep. 30, 2018
USD ($)
Options [Member]  
Intrinsic value of options outstanding $ 0
Warrants [Member]  
Intrinsic value of warrants outstanding $ 0
EXCEL 32 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 34 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 36 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 41 106 1 false 14 0 false 5 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://ctinanotech.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://ctinanotech.com/role/BalanceSheets Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://ctinanotech.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://ctinanotech.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) Sheet http://ctinanotech.com/role/StatementsOfChangesInStockholdersDeficit Condensed Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://ctinanotech.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Organization and Summary of Significant Accounting Policies Sheet http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies Organization and Summary of Significant Accounting Policies Notes 7 false false R8.htm 00000008 - Disclosure - 2. Agreement with Distributors Sheet http://ctinanotech.com/role/AgreementWithDistributors 2. Agreement with Distributors Notes 8 false false R9.htm 00000009 - Disclosure - 3. Stockholders' Deficit Sheet http://ctinanotech.com/role/StockholdersDeficit 3. Stockholders' Deficit Notes 9 false false R10.htm 00000010 - Disclosure - 4. Commitments and Contingencies Sheet http://ctinanotech.com/role/CommitmentsAndContingencies 4. Commitments and Contingencies Notes 10 false false R11.htm 00000011 - Disclosure - 1. Organization and Summary of Significant Accounting Policies (Policies) Sheet http://ctinanotech.com/role/SignificantAccountingPoliciesPolicies 1. Organization and Summary of Significant Accounting Policies (Policies) Policies http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies 11 false false R12.htm 00000012 - Disclosure - 3. Stockholders' Deficit (Tables) Sheet http://ctinanotech.com/role/StockholdersDeficitTables 3. Stockholders' Deficit (Tables) Tables http://ctinanotech.com/role/StockholdersDeficit 12 false false R13.htm 00000013 - Disclosure - 1. Organization and Summary of Significant Accounting Policies (Details Narrative) Sheet http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative 1. Organization and Summary of Significant Accounting Policies (Details Narrative) Details http://ctinanotech.com/role/SignificantAccountingPoliciesPolicies 13 false false R14.htm 00000014 - Disclosure - 2. Agreement with Distributors (Details Narrative) Sheet http://ctinanotech.com/role/AgreementWithDistributorsDetailsNarrative 2. Agreement with Distributors (Details Narrative) Details http://ctinanotech.com/role/AgreementWithDistributors 14 false false R15.htm 00000015 - Disclosure - 3. Stockholders' Deficit (Details - Option activity) Sheet http://ctinanotech.com/role/StockholdersDeficitDetails-OptionActivity 3. Stockholders' Deficit (Details - Option activity) Details http://ctinanotech.com/role/StockholdersDeficitTables 15 false false R16.htm 00000016 - Disclosure - 3. Stockholders' Deficit (Details - Options by exercise price) Sheet http://ctinanotech.com/role/StockholdersDeficitDetails-OptionsByExercisePrice 3. Stockholders' Deficit (Details - Options by exercise price) Details http://ctinanotech.com/role/StockholdersDeficitTables 16 false false R17.htm 00000017 - Disclosure - 3. Stockholders' Deficit (Details - Warrant activity) Sheet http://ctinanotech.com/role/StockholdersDeficitDetails-WarrantActivity 3. Stockholders' Deficit (Details - Warrant activity) Details http://ctinanotech.com/role/StockholdersDeficitTables 17 false false R18.htm 00000018 - Disclosure - 3. Stockholders' Deficit (Details - Warrants by exercise price) Sheet http://ctinanotech.com/role/StockholdersDeficitDetails-WarrantsByExercisePrice 3. Stockholders' Deficit (Details - Warrants by exercise price) Details http://ctinanotech.com/role/StockholdersDeficitTables 18 false false R19.htm 00000019 - Disclosure - 3. Stockholders' Deficit (Details Narrative) Sheet http://ctinanotech.com/role/StockholdersDeficitDetailsNarrative 3. Stockholders' Deficit (Details Narrative) Details http://ctinanotech.com/role/StockholdersDeficitTables 19 false false All Reports Book All Reports cvat-20180930.xml cvat-20180930.xsd cvat-20180930_cal.xml cvat-20180930_def.xml cvat-20180930_lab.xml cvat-20180930_pre.xml http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/srt/2018-01-31 http://fasb.org/us-gaap/2018-01-31 true true ZIP 38 0001144204-18-059762-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-18-059762-xbrl.zip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�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